Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,455989,half-life,"The time course of ethinyloestradiol concentration in plasma can be described by a 3-compartment model after intravenous injection and by a 2-compartment model after oral administration, because an early disposition phase with a half-life of about 15 minutes only becomes visible after i.v. injection.",Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455989/),min,15,517,DB00977,Ethinyl Estradiol
,455989,terminal half-life,"On an average, the terminal half-life of unchanged ethinyloestradiol level and total radioactivity was calculated to be about 1 day.",Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/455989/),d,1,518,DB00977,Ethinyl Estradiol
,725974,half life (t1/2),"The disappearance followed two exponentials, the first having a half life (t1/2) of 5.5 min and the second, apparently terminal exponential was also rapid (t1/2-69 min).",The pharmacokinetics of tritiated ethinylestradiol in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725974/),min,5.5,610,DB00977,Ethinyl Estradiol
,725974,t1/2,"The disappearance followed two exponentials, the first having a half life (t1/2) of 5.5 min and the second, apparently terminal exponential was also rapid (t1/2-69 min).",The pharmacokinetics of tritiated ethinylestradiol in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725974/),min,69,611,DB00977,Ethinyl Estradiol
,725974,plasma clearance,The plasma clearance was 150 ml/min which suggests almost total clearance of this steroid during a single passage through the liver.,The pharmacokinetics of tritiated ethinylestradiol in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/725974/),[ml] / [min],150,612,DB00977,Ethinyl Estradiol
,3814762,Elimination half-lives,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,1.98,8399,DB00977,Ethinyl Estradiol
,3814762,Elimination half-lives,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,2.73,8400,DB00977,Ethinyl Estradiol
,3814762,total clearances,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],4.20,8401,DB00977,Ethinyl Estradiol
,3814762,total clearances,"Elimination half-lives were shorter in the patients than in the 9 healthy subjects (1.98 +/- 0.48 versus 2.73 +/- 0.76 h, mean +/- SD, 0.02 less than p less than 0.05), and total clearances higher (4.20 +/- 0.53 versus 2.96 +/- 0.54 ml X min-1 X kg-1, p less than 0.02), while the volumes of distribution did not differ significantly.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.96,8402,DB00977,Ethinyl Estradiol
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,4.75,8403,DB00977,Ethinyl Estradiol
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,3.05,8404,DB00977,Ethinyl Estradiol
,3814762,elimination half-life,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],1.91,8405,DB00977,Ethinyl Estradiol
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,3.05,8406,DB00977,Ethinyl Estradiol
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),h,2.33,8407,DB00977,Ethinyl Estradiol
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],1.91,8408,DB00977,Ethinyl Estradiol
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.95,8409,DB00977,Ethinyl Estradiol
,3814762,total clearance,"Among the healthy subjects, the oral contraceptive group exhibited a longer elimination half-life, and a lower total clearance, than each of the other two groups, who gave similar results (respectively 4.75 +/- 1.27, 3.05 +/- 0.75, and 2.33 +/- 0.66 h, p less than or equal to 0.05; 1.91 +/- 0.57, 2.95 +/- 0.60, and 2.97 +/- 0.57 ml X min-1 X kg-1, p less than or equal to 0.05); the volumes of distribution were not significantly different.","Modified elimination of prednisolone in epileptic patients on carbamazepine monotherapy, and in women using low-dose oral contraceptives. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814762/),[ml] / [kg·min],2.97,8410,DB00977,Ethinyl Estradiol
≤,27584548,"AUC24,ss ratio","Opioids, antipsychotics, anti-epileptics, antidiabetics and non-ethinyl estradiol-containing hormone replacement therapies appeared to have an effect (AUC24,ss ratio ≤0.5 or ≥2.0) on paritaprevir exposures.","Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27584548/),,0.5,8521,DB00977,Ethinyl Estradiol
≥,27584548,"AUC24,ss ratio","Opioids, antipsychotics, anti-epileptics, antidiabetics and non-ethinyl estradiol-containing hormone replacement therapies appeared to have an effect (AUC24,ss ratio ≤0.5 or ≥2.0) on paritaprevir exposures.","Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27584548/),,2.0,8522,DB00977,Ethinyl Estradiol
,29198449,Cmax,"Mean (SD) Cmax and AUC0-∞ values of ethinylestradiol were 66.7 (16.3) pg/mL and 693 (268) pg · h/mL, respectively, following the oral contraceptive alone, and 72.7 (25.5) pg/mL and 740 (235) pg · h/mL, respectively, when the oral contraceptive was preceded by flibanserin.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[pg] / [ml],66.7,10002,DB00977,Ethinyl Estradiol
,29198449,Cmax,"Mean (SD) Cmax and AUC0-∞ values of ethinylestradiol were 66.7 (16.3) pg/mL and 693 (268) pg · h/mL, respectively, following the oral contraceptive alone, and 72.7 (25.5) pg/mL and 740 (235) pg · h/mL, respectively, when the oral contraceptive was preceded by flibanserin.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[pg] / [ml],72.7,10003,DB00977,Ethinyl Estradiol
,29198449,AUC0-∞,"Mean (SD) Cmax and AUC0-∞ values of ethinylestradiol were 66.7 (16.3) pg/mL and 693 (268) pg · h/mL, respectively, following the oral contraceptive alone, and 72.7 (25.5) pg/mL and 740 (235) pg · h/mL, respectively, when the oral contraceptive was preceded by flibanserin.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[h·pg] / [ml],693,10004,DB00977,Ethinyl Estradiol
,29198449,AUC0-∞,"Mean (SD) Cmax and AUC0-∞ values of ethinylestradiol were 66.7 (16.3) pg/mL and 693 (268) pg · h/mL, respectively, following the oral contraceptive alone, and 72.7 (25.5) pg/mL and 740 (235) pg · h/mL, respectively, when the oral contraceptive was preceded by flibanserin.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[h·pg] / [ml],740,10005,DB00977,Ethinyl Estradiol
,29198449,Cmax,"Similarly, the mean (SD) Cmax and AUC0-∞ values of levonorgestrel were 5.0 (1.6) ng/mL and 52.2 (18.7) ng · h/mL, respectively, with the oral contraceptive alone, and 5.0 (1.6) ng/mL and 53.3 (20.4) ng · h/mL, respectively, following flibanserin; again, in both cases, the 90% CIs of the reference/test ratios were within the range of 80% to 125%, indicating that flibanserin had no significant effect on the pharmacokinetic properties of levonorgestrel.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[ng] / [ml],5.0,10006,DB00977,Ethinyl Estradiol
,29198449,AUC0-∞,"Similarly, the mean (SD) Cmax and AUC0-∞ values of levonorgestrel were 5.0 (1.6) ng/mL and 52.2 (18.7) ng · h/mL, respectively, with the oral contraceptive alone, and 5.0 (1.6) ng/mL and 53.3 (20.4) ng · h/mL, respectively, following flibanserin; again, in both cases, the 90% CIs of the reference/test ratios were within the range of 80% to 125%, indicating that flibanserin had no significant effect on the pharmacokinetic properties of levonorgestrel.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[h·ng] / [ml],52.2,10007,DB00977,Ethinyl Estradiol
,29198449,AUC0-∞,"Similarly, the mean (SD) Cmax and AUC0-∞ values of levonorgestrel were 5.0 (1.6) ng/mL and 52.2 (18.7) ng · h/mL, respectively, with the oral contraceptive alone, and 5.0 (1.6) ng/mL and 53.3 (20.4) ng · h/mL, respectively, following flibanserin; again, in both cases, the 90% CIs of the reference/test ratios were within the range of 80% to 125%, indicating that flibanserin had no significant effect on the pharmacokinetic properties of levonorgestrel.",Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198449/),[h·ng] / [ml],53.3,10008,DB00977,Ethinyl Estradiol
,2766722,C.V.s,"Intra-individual C.V.s were 41% and 42%, respectively.","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,41,11325,DB00977,Ethinyl Estradiol
,2766722,C.V.s,"Intra-individual C.V.s were 41% and 42%, respectively.","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,42,11326,DB00977,Ethinyl Estradiol
,2766722,AUC,"For norethindrone, the AUC was larger with the 1 + 50 formulations than with the 1 + 35 group (87.9 vs. 72.8 pg hr/ml).","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),[h·pg] / [ml],87.9,11327,DB00977,Ethinyl Estradiol
,2766722,AUC,"For norethindrone, the AUC was larger with the 1 + 50 formulations than with the 1 + 35 group (87.9 vs. 72.8 pg hr/ml).","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),[h·pg] / [ml],72.8,11328,DB00977,Ethinyl Estradiol
,2766722,Cmax,"Additionally, the Cmax values were larger for the 1/50 group (17.7 vs. 14.0).","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),,17.7,11329,DB00977,Ethinyl Estradiol
,2766722,Cmax,"Additionally, the Cmax values were larger for the 1/50 group (17.7 vs. 14.0).","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),,14.0,11330,DB00977,Ethinyl Estradiol
,2766722,C.V.,The inter-individual C.V. averaged 56% for both dosage groups.,"Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,56,11331,DB00977,Ethinyl Estradiol
,2766722,C.V.s,"The intra-individual C.V.s were 17% and 46% for the 1 + 35 and 1 + 50 groups, respectively.","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,17,11332,DB00977,Ethinyl Estradiol
,2766722,C.V.s,"The intra-individual C.V.s were 17% and 46% for the 1 + 35 and 1 + 50 groups, respectively.","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,46,11333,DB00977,Ethinyl Estradiol
,28982161,peak progesterone levels,"Mean peak progesterone levels were 4.4 ± 1.8 ng mL-1 prior to IVR insertion and 0.075 ± 0.064 ng mL-1 for 5 weeks after insertion, suggesting that systemic EE/ENG levels were sufficient to suppress menstruation.","Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982161/),[ng] / [ml],4.4,11833,DB00977,Ethinyl Estradiol
,28982161,peak progesterone levels,"Mean peak progesterone levels were 4.4 ± 1.8 ng mL-1 prior to IVR insertion and 0.075 ± 0.064 ng mL-1 for 5 weeks after insertion, suggesting that systemic EE/ENG levels were sufficient to suppress menstruation.","Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982161/),[ng] / [ml],0.075,11834,DB00977,Ethinyl Estradiol
,28982161,release rates,"The TAF2 and ACV release rates and resulting vaginal tissue drug concentrations (medians: TFV, 2.4 ng mg-1; ACV, 0.2 ng mg-1) may be sufficient to protect against HIV and HSV infection, respectively.","Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982161/),[ng] / [mg],2.4,11835,DB00977,Ethinyl Estradiol
,28982161,release rates,"The TAF2 and ACV release rates and resulting vaginal tissue drug concentrations (medians: TFV, 2.4 ng mg-1; ACV, 0.2 ng mg-1) may be sufficient to protect against HIV and HSV infection, respectively.","Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28982161/),[ng] / [mg],0.2,11836,DB00977,Ethinyl Estradiol
,3112991,total body clearance,The total body clearance of ethinyloestradiol was significantly higher in the patients with cystic fibrosis (0.61 (SD 0.19) l/h/kg) than in control women (0.32 (0.16) l/h/kg; p less than 0.02).,Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3112991/),[l] / [h·kg],0.61,12663,DB00977,Ethinyl Estradiol
,3112991,total body clearance,The total body clearance of ethinyloestradiol was significantly higher in the patients with cystic fibrosis (0.61 (SD 0.19) l/h/kg) than in control women (0.32 (0.16) l/h/kg; p less than 0.02).,Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3112991/),[l] / [h·kg],0.32,12664,DB00977,Ethinyl Estradiol
,3112991,oral bioavailability,"In addition, the oral bioavailability of ethinyloestradiol was greater in women with cystic fibrosis than in controls (76.9% (11.7%) compared with 47.3% (7.5%); p less than 0.001).",Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3112991/),%,76.9,12665,DB00977,Ethinyl Estradiol
,3112991,oral bioavailability,"In addition, the oral bioavailability of ethinyloestradiol was greater in women with cystic fibrosis than in controls (76.9% (11.7%) compared with 47.3% (7.5%); p less than 0.001).",Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3112991/),%,47.3,12666,DB00977,Ethinyl Estradiol
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],116-160,24508,DB00977,Ethinyl Estradiol
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],55-78,24509,DB00977,Ethinyl Estradiol
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],30-70,24510,DB00977,Ethinyl Estradiol
,7285572,half-life of elimination,"Calculation of the half-lives for absorption, distribution and elimination showed wide variations between subjects, the half-life of elimination varying from 2.5 h to more than 30 h.",Pharmacokinetics of ethynyloestradiol in women for different populations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285572/),h,2.5,26692,DB00977,Ethinyl Estradiol
more,7285572,half-life of elimination,"Calculation of the half-lives for absorption, distribution and elimination showed wide variations between subjects, the half-life of elimination varying from 2.5 h to more than 30 h.",Pharmacokinetics of ethynyloestradiol in women for different populations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285572/),h,30,26693,DB00977,Ethinyl Estradiol
,23064958,steady-state plasma concentration,"The mean ± SD vismodegib steady-state plasma concentration (Day 8, N = 51) was 20.6 ± 9.72 μM (range 7.93-62.4 μM).",Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064958/),μM,20.6,30393,DB00977,Ethinyl Estradiol
,26037079,C max,"After the single dose administration, the C max of EE and LNG were 44.76±18.64 pg/mL and 2.256±1.008 ng/mL, respectively.",Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26037079/),[pg] / [ml],44.76,31520,DB00977,Ethinyl Estradiol
,26037079,C max,"After the single dose administration, the C max of EE and LNG were 44.76±18.64 pg/mL and 2.256±1.008 ng/mL, respectively.",Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26037079/),[ng] / [ml],2.256,31521,DB00977,Ethinyl Estradiol
,31194965,AUClast,"LNG AUClast increased by 32.6% (312±60.9 vs. 243±82.6 ng/mL*h, p=.033, n=5) in women taking ritonavir compared to the control group (n=10).",Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [h·ml],312,38024,DB00977,Ethinyl Estradiol
,31194965,AUClast,"LNG AUClast increased by 32.6% (312±60.9 vs. 243±82.6 ng/mL*h, p=.033, n=5) in women taking ritonavir compared to the control group (n=10).",Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [h·ml],243,38025,DB00977,Ethinyl Estradiol
,31194965,Cmax,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],9.68,38026,DB00977,Ethinyl Estradiol
,31194965,Cmax,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],7.62,38027,DB00977,Ethinyl Estradiol
,31194965,Cmin,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],4.97,38028,DB00977,Ethinyl Estradiol
,31194965,Cmin,The Cmax (9.68±1.81 vs. 7.62±2.29 ng/mL) and Cmin (4.97±1.15 vs. 3.70±1.29 ng/mL) were also higher in the ritonavir arm.,Effects of ritonavir-boosted protease inhibitors on combined oral contraceptive pharmacokinetics and pharmacodynamics in HIV-positive women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31194965/),[ng] / [ml],3.70,38029,DB00977,Ethinyl Estradiol
,15244497,area under the plasma concentration-time curve from zero to 24 hours (AUC24),"In Study I (tazarotene 1.1 mg), the area under the plasma concentration-time curve from zero to 24 hours (AUC24) and the peak concentration in plasma (Cmax) for tazarotenic acid were 121 +/- 27 microg.",Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244497/),μg,121,38951,DB00977,Ethinyl Estradiol
,15244497,AUC24,"In Study II (tazarotene 6 mg), AUC24 and Cmax for tazarotenic acid were 379 +/- 78 microg.",Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244497/),μg,379,38952,DB00977,Ethinyl Estradiol
,18294327,AUC(tau),"Voriconazole geometric mean AUC(tau) and C(max) increased 46% (12 682-18 495 ng h ml(-1); 90% confidence interval [CI] 32, 61) and 14% (2485-2840 ng ml(-1); 90% CI 3, 27), respectively, when co-administered with oral contraceptive vs. voriconazole alone.",Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294327/),[h·ng] / [ml],12,43795,DB00977,Ethinyl Estradiol
,10438721,clearance rate,17alpha-Ethinyl estradiol (EE) treatment resulted in a significant increase in the clearance rate of recombinant human t-PA in mice (0.46 mL/min in treated mice v 0. 32 mL/min in controls; P <.01).,Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.46,44028,DB00977,Ethinyl Estradiol
,10438721,clearance rate,17alpha-Ethinyl estradiol (EE) treatment resulted in a significant increase in the clearance rate of recombinant human t-PA in mice (0.46 mL/min in treated mice v 0. 32 mL/min in controls; P <.01).,Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0. 32,44029,DB00977,Ethinyl Estradiol
,10438721,area under the curve [AUC],"The clearance of endogenous, bradykinin-released t-PA in rats was also significantly increased after EE treatment (area under the curve [AUC], 24.9 ng/mL. min in treated animals v 31.9 ng/mL. min in controls; P <.05).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ng] / [min·ml],24.9,44030,DB00977,Ethinyl Estradiol
,10438721,area under the curve [AUC],"The clearance of endogenous, bradykinin-released t-PA in rats was also significantly increased after EE treatment (area under the curve [AUC], 24.9 ng/mL. min in treated animals v 31.9 ng/mL. min in controls; P <.05).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ng] / [min·ml],31.9,44031,DB00977,Ethinyl Estradiol
,10438721,clearance,"Inhibition of LRP by intravenous injection of receptor-associated protein (RAP) as a recombinant fusion protein with Salmonella japonicum glutathione S-transferase (GST) significantly retarded t-PA clearance in control mice (from 0.41 to 0.25 mL/min; n = 5, P <.001) and EE-treated mice (from 0.66 to 0.35 mL/min; n = 5, P <.005), but did not eliminate the difference in clearance capacity between the 2 experimental groups.",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.41 to 0.25,44032,DB00977,Ethinyl Estradiol
,10438721,clearance,"Inhibition of LRP by intravenous injection of receptor-associated protein (RAP) as a recombinant fusion protein with Salmonella japonicum glutathione S-transferase (GST) significantly retarded t-PA clearance in control mice (from 0.41 to 0.25 mL/min; n = 5, P <.001) and EE-treated mice (from 0.66 to 0.35 mL/min; n = 5, P <.005), but did not eliminate the difference in clearance capacity between the 2 experimental groups.",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.66 to 0.35,44033,DB00977,Ethinyl Estradiol
,10438721,clearances,"In contrast, administration of mannan, a mannose receptor antagonist, resulted in identical clearances (0.22 mL/min in controls and 0.24 mL/min in EE-treated mice).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.22,44034,DB00977,Ethinyl Estradiol
,10438721,clearances,"In contrast, administration of mannan, a mannose receptor antagonist, resulted in identical clearances (0.22 mL/min in controls and 0.24 mL/min in EE-treated mice).",Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potently enhanced mannose receptor expression in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10438721/),[ml] / [min],0.24,44035,DB00977,Ethinyl Estradiol
,24161160,AUC24h,"Norethindrone pharmacokinetics were unaffected by rilpivirine (AUC24h: 0.89, 0.84 - 0.94; Cmin: 0.99, 0.90 - 1.08; Cmax: 0.94, 0.83 - 1.06).",Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24161160/),,0,49051,DB00977,Ethinyl Estradiol
,3096634,relative bioavailability (Fr),The relative bioavailability (Fr) of LNG in the tablet with respect to the solution was 107%; thus the two formulations were bioequivalent with respect to LNG.,The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096634/),%,107,49378,DB00977,Ethinyl Estradiol
,3096634,relative bioavailability,"The relative bioavailability of EE, however, was significantly lower for the tablet (Fr 83%) compared to the solution.",The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096634/),%,83,49379,DB00977,Ethinyl Estradiol
,3096634,Fr,"The relative bioavailability of EE, however, was significantly lower for the tablet (Fr 83%) compared to the solution.",The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3096634/),%,83,49380,DB00977,Ethinyl Estradiol
,1819548,half-life,The average half-life of E3 ranged from 1.5 to 5.3 h after the administration of E3.,Plasma estriol levels after intramuscular injection of estriol and two of its esters. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1819548/),h,1.5 to 5.3,49499,DB00977,Ethinyl Estradiol
,1819548,areas under the curve,"The average areas under the curve (in nmol.l-1.h) of E3 were between 82.5 and 161 after the administration of E3-prop or E3-hex, and between 27.1 and 37.9 when E3 had been given.",Plasma estriol levels after intramuscular injection of estriol and two of its esters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1819548/),[h·nM] / [l],82.5 and 161,49500,DB00977,Ethinyl Estradiol
,1819548,areas under the curve,"The average areas under the curve (in nmol.l-1.h) of E3 were between 82.5 and 161 after the administration of E3-prop or E3-hex, and between 27.1 and 37.9 when E3 had been given.",Plasma estriol levels after intramuscular injection of estriol and two of its esters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1819548/),[h·nM] / [l],27.1 and 37.9,49501,DB00977,Ethinyl Estradiol
,8922877,terminal half-lives,"The mean terminal half-lives were calculated to be 12.3 +/- 12.4, 28.7 +/- 9.6, and 26.1 +/- 11.1 h for ZK 136295, ZK 115194, and EE2 respectively.",Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922877/),h,12.3,57359,DB00977,Ethinyl Estradiol
,8922877,terminal half-lives,"The mean terminal half-lives were calculated to be 12.3 +/- 12.4, 28.7 +/- 9.6, and 26.1 +/- 11.1 h for ZK 136295, ZK 115194, and EE2 respectively.",Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922877/),h,28.7,57360,DB00977,Ethinyl Estradiol
,8922877,terminal half-lives,"The mean terminal half-lives were calculated to be 12.3 +/- 12.4, 28.7 +/- 9.6, and 26.1 +/- 11.1 h for ZK 136295, ZK 115194, and EE2 respectively.",Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922877/),h,26.1,57361,DB00977,Ethinyl Estradiol
,8922877,absolute bioavailability,"After oral administration of 120 micrograms, the absolute bioavailability was calculated to be about 40% for ZK 136295 as well as for EE2 with a high inter-individual variation (variation coefficient: 44 and 67%).",Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922877/),%,40,57362,DB00977,Ethinyl Estradiol
,8922877,absolute bioavailability,"Following single oral administration of 240 micrograms ZK 115194, the absolute bioavailability amounted to 33 +/- 19%.",Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922877/),%,33,57363,DB00977,Ethinyl Estradiol
,3746133,rapid decay constant,"During contraceptive steroid intake, both rapid and slow decay constants and the calculated plasma clearance rates were significantly increased (mean values: rapid decay constant, control 0.048 versus treated 0.101 min-1, P less than 0.05; slow decay constant, 0.004 versus 0.014 min-1, P less than 0.01; plasma clearance 74 versus 115 ml/min, P less than 0.025) indicating enhanced hepatic uptake of chylomicron remnants and probably an increased hepatic uptake of higher density lipoproteins (d greater than 1.006 g/ml).",Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746133/),1/[min],0.048,57384,DB00977,Ethinyl Estradiol
,3746133,rapid decay constant,"During contraceptive steroid intake, both rapid and slow decay constants and the calculated plasma clearance rates were significantly increased (mean values: rapid decay constant, control 0.048 versus treated 0.101 min-1, P less than 0.05; slow decay constant, 0.004 versus 0.014 min-1, P less than 0.01; plasma clearance 74 versus 115 ml/min, P less than 0.025) indicating enhanced hepatic uptake of chylomicron remnants and probably an increased hepatic uptake of higher density lipoproteins (d greater than 1.006 g/ml).",Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746133/),1/[min],0.101,57385,DB00977,Ethinyl Estradiol
,3746133,slow decay constant,"During contraceptive steroid intake, both rapid and slow decay constants and the calculated plasma clearance rates were significantly increased (mean values: rapid decay constant, control 0.048 versus treated 0.101 min-1, P less than 0.05; slow decay constant, 0.004 versus 0.014 min-1, P less than 0.01; plasma clearance 74 versus 115 ml/min, P less than 0.025) indicating enhanced hepatic uptake of chylomicron remnants and probably an increased hepatic uptake of higher density lipoproteins (d greater than 1.006 g/ml).",Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746133/),1/[min],0.004,57386,DB00977,Ethinyl Estradiol
,3746133,slow decay constant,"During contraceptive steroid intake, both rapid and slow decay constants and the calculated plasma clearance rates were significantly increased (mean values: rapid decay constant, control 0.048 versus treated 0.101 min-1, P less than 0.05; slow decay constant, 0.004 versus 0.014 min-1, P less than 0.01; plasma clearance 74 versus 115 ml/min, P less than 0.025) indicating enhanced hepatic uptake of chylomicron remnants and probably an increased hepatic uptake of higher density lipoproteins (d greater than 1.006 g/ml).",Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746133/),1/[min],0.014,57387,DB00977,Ethinyl Estradiol
,3746133,plasma clearance,"During contraceptive steroid intake, both rapid and slow decay constants and the calculated plasma clearance rates were significantly increased (mean values: rapid decay constant, control 0.048 versus treated 0.101 min-1, P less than 0.05; slow decay constant, 0.004 versus 0.014 min-1, P less than 0.01; plasma clearance 74 versus 115 ml/min, P less than 0.025) indicating enhanced hepatic uptake of chylomicron remnants and probably an increased hepatic uptake of higher density lipoproteins (d greater than 1.006 g/ml).",Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746133/),[ml] / [min],74,57388,DB00977,Ethinyl Estradiol
,3746133,plasma clearance,"During contraceptive steroid intake, both rapid and slow decay constants and the calculated plasma clearance rates were significantly increased (mean values: rapid decay constant, control 0.048 versus treated 0.101 min-1, P less than 0.05; slow decay constant, 0.004 versus 0.014 min-1, P less than 0.01; plasma clearance 74 versus 115 ml/min, P less than 0.025) indicating enhanced hepatic uptake of chylomicron remnants and probably an increased hepatic uptake of higher density lipoproteins (d greater than 1.006 g/ml).",Contraceptive steroids increase hepatic uptake of chylomicron remnants in healthy young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746133/),[ml] / [min],115,57389,DB00977,Ethinyl Estradiol
,22299599,clearance,"Midazolam clearance, a surrogate measure of CYP3A4/5 activity, was significantly decreased upon COC use (63.3 l h(-1) vs. 53.9 l h(-1), P < 0.05).",Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22299599/),[l] / [h],63.3,64136,DB00977,Ethinyl Estradiol
,22299599,clearance,"Midazolam clearance, a surrogate measure of CYP3A4/5 activity, was significantly decreased upon COC use (63.3 l h(-1) vs. 53.9 l h(-1), P < 0.05).",Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22299599/),[l] / [h],53.9,64137,DB00977,Ethinyl Estradiol
,428229,terminal elimination half lives,"After the peak, NE plasma levels declined in two phases, with a mean terminal elimination half lives of 4 to 6.9h.",Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/428229/),h,4 to 6.9,65808,DB00977,Ethinyl Estradiol
,28990653,inhibition constant (Ki ),The in-vitro inhibition constant (Ki ) value for paritaprevir vs EE on average was 20 μm and was consistent with a competitive inhibition mechanism.,Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28990653/),μm,20,68856,DB00977,Ethinyl Estradiol
,6786829,peak,Plasma concentrations of Ng rise to a peak of 3.6 ng/ml after an oral dose of 150 microgram and to 5.0 ng/ml after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[ng] / [ml],3.6,71125,DB00977,Ethinyl Estradiol
,6786829,peak,Plasma concentrations of Ng rise to a peak of 3.6 ng/ml after an oral dose of 150 microgram and to 5.0 ng/ml after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[ng] / [ml],5.0,71126,DB00977,Ethinyl Estradiol
,6786829,half-lives,"Following the intravenous administration of Ng, plasma concentrations of the steroid decline bi-exponentially with mean half-lives of 0.76 and 11.55 hours.",The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),h,0.76,71127,DB00977,Ethinyl Estradiol
,6786829,half-lives,"Following the intravenous administration of Ng, plasma concentrations of the steroid decline bi-exponentially with mean half-lives of 0.76 and 11.55 hours.",The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),h,11.55,71128,DB00977,Ethinyl Estradiol
,6786829,systemic bioavailability,Comparison of the results of the intravenous and oral administration of the steroid show a mean systemic bioavailability of 89% after the 150 microgram dose and 99% after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),%,89,71129,DB00977,Ethinyl Estradiol
,6786829,systemic bioavailability,Comparison of the results of the intravenous and oral administration of the steroid show a mean systemic bioavailability of 89% after the 150 microgram dose and 99% after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),%,99,71130,DB00977,Ethinyl Estradiol
,6786829,peak values,The peak values after oral dosing were 103 pg/ml and were reached by 1.0 hour in all subjects.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[pg] / [ml],103,71131,DB00977,Ethinyl Estradiol
,2142929,maximum EE2,Mean maximum EE2 levels of 106-129 pg/ml were found 1.6-1.8 h after pill intake and AUC0-4 h accounted for 329-374 pg.h.ml-1.,"Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142929/),[pg] / [ml],106-129,75399,DB00977,Ethinyl Estradiol
,2142929,AUC0-4 h,Mean maximum EE2 levels of 106-129 pg/ml were found 1.6-1.8 h after pill intake and AUC0-4 h accounted for 329-374 pg.h.ml-1.,"Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2142929/),[h·pg] / [ml],329-374,75400,DB00977,Ethinyl Estradiol
,1802819,terminal half-life,"This increase was due to an increased dose of LNG according to the triphasic dose regimen, a concomitantly ethinylestradiol-induced increase in SHBG and due to pharmacokinetic accumulation, since LNG had a terminal half-life of approximately 28.5 h and the dosing interval was 24 h.",Pharmacokinetics of levonorgestrel in 18 women after 1 month of treatment with a triphasic oral contraceptive. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1802819/),h,28.5,83453,DB00977,Ethinyl Estradiol
,6132698,volume of distribution (Vd),"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.33,85924,DB00977,Ethinyl Estradiol
,6132698,volume of distribution (Vd),"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.45,85925,DB00977,Ethinyl Estradiol
,6132698,elimination t1/2,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,13.1,85926,DB00977,Ethinyl Estradiol
,6132698,elimination t1/2,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,12.2,85927,DB00977,Ethinyl Estradiol
,6132698,total clearance,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.25,85928,DB00977,Ethinyl Estradiol
,6132698,total clearance,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.50,85929,DB00977,Ethinyl Estradiol
,6132698,free fraction in,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,10.3,85930,DB00977,Ethinyl Estradiol
,6132698,Vd,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.05,85931,DB00977,Ethinyl Estradiol
,6132698,Vd,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.19,85932,DB00977,Ethinyl Estradiol
,6132698,t1/2,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,7.6,85933,DB00977,Ethinyl Estradiol
,6132698,t1/2,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,7.2,85934,DB00977,Ethinyl Estradiol
,6132698,total clearance,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.60,85935,DB00977,Ethinyl Estradiol
,6132698,total clearance,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],2.03,85936,DB00977,Ethinyl Estradiol
,6132698,free fraction,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,4.6,85937,DB00977,Ethinyl Estradiol
,6132698,free fraction,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,4.9,85938,DB00977,Ethinyl Estradiol
,11090892,C(max),"The pattern of VTG induction was similar for all doses of EE(2), with a 12-h lag-time before increase from basal levels (0.006-0.008 microg/ml), then increasing sharply to maximum levels within 7-9 days (C(max)=0.05, 711, 1521 and 2547 microg/ml VTG for the 0.001, 0.1, 1.0 and 10.0 mg/kg doses, respectively).",Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),[μg] / [ml],0.05,86696,DB00977,Ethinyl Estradiol
,11090892,C(max),"The pattern of VTG induction was similar for all doses of EE(2), with a 12-h lag-time before increase from basal levels (0.006-0.008 microg/ml), then increasing sharply to maximum levels within 7-9 days (C(max)=0.05, 711, 1521 and 2547 microg/ml VTG for the 0.001, 0.1, 1.0 and 10.0 mg/kg doses, respectively).",Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),[μg] / [ml],711,86697,DB00977,Ethinyl Estradiol
,11090892,C(max),"The pattern of VTG induction was similar for all doses of EE(2), with a 12-h lag-time before increase from basal levels (0.006-0.008 microg/ml), then increasing sharply to maximum levels within 7-9 days (C(max)=0.05, 711, 1521 and 2547 microg/ml VTG for the 0.001, 0.1, 1.0 and 10.0 mg/kg doses, respectively).",Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),[μg] / [ml],1521,86698,DB00977,Ethinyl Estradiol
,11090892,C(max),"The pattern of VTG induction was similar for all doses of EE(2), with a 12-h lag-time before increase from basal levels (0.006-0.008 microg/ml), then increasing sharply to maximum levels within 7-9 days (C(max)=0.05, 711, 1521 and 2547 microg/ml VTG for the 0.001, 0.1, 1.0 and 10.0 mg/kg doses, respectively).",Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),[μg] / [ml],2547,86699,DB00977,Ethinyl Estradiol
,11090892,elimination half-life,"After induction by EE(2), VTG declined mono-exponentially with an elimination half-life of 42-49 h.",Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),h,42-49,86700,DB00977,Ethinyl Estradiol
,11090892,half-life,The half-life of VTG increased to 145 h in the 10 mg/kg treated fish.,Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),h,145,86701,DB00977,Ethinyl Estradiol
,11090892,apparent steady-state volume of distribution,"After direct injection of VTG, plasma levels declined tri-exponentially with an apparent steady-state volume of distribution of 837 ml/kg; total body clearance was 31.1 ml/h per kg, and the elimination half-life was 43.7 h.",Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),[ml] / [kg],837,86702,DB00977,Ethinyl Estradiol
,11090892,total body clearance,"After direct injection of VTG, plasma levels declined tri-exponentially with an apparent steady-state volume of distribution of 837 ml/kg; total body clearance was 31.1 ml/h per kg, and the elimination half-life was 43.7 h.",Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),[ml] / [h·kg],31.1,86703,DB00977,Ethinyl Estradiol
,11090892,elimination half-life,"After direct injection of VTG, plasma levels declined tri-exponentially with an apparent steady-state volume of distribution of 837 ml/kg; total body clearance was 31.1 ml/h per kg, and the elimination half-life was 43.7 h.",Dose-response relationships and pharmacokinetics of vitellogenin in rainbow trout after intravascular administration of 17alpha-ethynylestradiol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11090892/),h,43.7,86704,DB00977,Ethinyl Estradiol
,14663455,oral clearance,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],8.2,91245,DB00977,Ethinyl Estradiol
,14663455,oral clearance,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],9.5,91246,DB00977,Ethinyl Estradiol
,14663455,half-life,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),h,23.4,91247,DB00977,Ethinyl Estradiol
,14663455,half-life,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),h,12.2,91248,DB00977,Ethinyl Estradiol
,14663455,oral clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],109.2,91249,DB00977,Ethinyl Estradiol
,14663455,oral clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],166.7,91250,DB00977,Ethinyl Estradiol
,14663455,systemic clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],37.7,91251,DB00977,Ethinyl Estradiol
,14663455,systemic clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],39.0,91252,DB00977,Ethinyl Estradiol
,14663455,oral clearance,The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005).,The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],215.9,91253,DB00977,Ethinyl Estradiol
,14663455,oral clearance,The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005).,The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],97.5,91254,DB00977,Ethinyl Estradiol
,19015839,AUC(0-24),"Before the co-administration of Ze 117 on day 7, the geometric mean (geometric coefficient of variation) for the AUC(0-24) of ethinylestradiol was 152.53 pg.h/ml (87.39%) and after co-administration on day 21 it was 196.57 pg.h/ml (78.14%).",St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015839/),[h·pg] / [ml],152.53,91434,DB00977,Ethinyl Estradiol
,19015839,AUC(0-24),"Before the co-administration of Ze 117 on day 7, the geometric mean (geometric coefficient of variation) for the AUC(0-24) of ethinylestradiol was 152.53 pg.h/ml (87.39%) and after co-administration on day 21 it was 196.57 pg.h/ml (78.14%).",St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19015839/),[h·pg] / [ml],196.57,91435,DB00977,Ethinyl Estradiol
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,27.3,94875,DB00977,Ethinyl Estradiol
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,27.7,94876,DB00977,Ethinyl Estradiol
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,29.6,94877,DB00977,Ethinyl Estradiol
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],59.3,94878,DB00977,Ethinyl Estradiol
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],58.2,94879,DB00977,Ethinyl Estradiol
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],55.8,94880,DB00977,Ethinyl Estradiol
,7059433,elimination half-life,3 The use of OC-steroids did not significantly alter the elimination half-life of nitrazepam: 30.6 +/- 2.3 and 31.2 +/- 2.2 h in the first and second half of the pill cycle.,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,30.6,94881,DB00977,Ethinyl Estradiol
,7059433,elimination half-life,3 The use of OC-steroids did not significantly alter the elimination half-life of nitrazepam: 30.6 +/- 2.3 and 31.2 +/- 2.2 h in the first and second half of the pill cycle.,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,31.2,94882,DB00977,Ethinyl Estradiol
,7059433,total nitrazepam clearance,The total nitrazepam clearance in these females (46.6 +/- 4.6 and 45.6 +/- 4.1 ml/min) was significantly lower than in males (P less than 0.05).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],46.6,94883,DB00977,Ethinyl Estradiol
,7059433,total nitrazepam clearance,The total nitrazepam clearance in these females (46.6 +/- 4.6 and 45.6 +/- 4.1 ml/min) was significantly lower than in males (P less than 0.05).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],45.6,94884,DB00977,Ethinyl Estradiol
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,11.4,94885,DB00977,Ethinyl Estradiol
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,12.4,94886,DB00977,Ethinyl Estradiol
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,13.5,94887,DB00977,Ethinyl Estradiol
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],323,94888,DB00977,Ethinyl Estradiol
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],530,94889,DB00977,Ethinyl Estradiol
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],459,94890,DB00977,Ethinyl Estradiol
,15722070,Cmax,"Vaginal administration of double the standard dose of the Yuzpe regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=14.6 ng/mL, p=.038) and a later Tmax (5.9 vs. 2.0 h, p=.066) for levonorgestrel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),[ng] / [ml],5.4,97600,DB00977,Ethinyl Estradiol
,15722070,Cmax,"Vaginal administration of double the standard dose of the Yuzpe regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=14.6 ng/mL, p=.038) and a later Tmax (5.9 vs. 2.0 h, p=.066) for levonorgestrel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),[ng] / [ml],14.6,97601,DB00977,Ethinyl Estradiol
,15722070,Tmax,"Vaginal administration of double the standard dose of the Yuzpe regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=14.6 ng/mL, p=.038) and a later Tmax (5.9 vs. 2.0 h, p=.066) for levonorgestrel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),h,5.9,97602,DB00977,Ethinyl Estradiol
,15722070,Tmax,"Vaginal administration of double the standard dose of the Yuzpe regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=14.6 ng/mL, p=.038) and a later Tmax (5.9 vs. 2.0 h, p=.066) for levonorgestrel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),h,2.0,97603,DB00977,Ethinyl Estradiol
,15722070,Relative bioavailabilities,"Relative bioavailabilities for levonorgestrel and ethinyl estradiol were 58% and 175%, respectively.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),%,58,97604,DB00977,Ethinyl Estradiol
,15722070,Relative bioavailabilities,"Relative bioavailabilities for levonorgestrel and ethinyl estradiol were 58% and 175%, respectively.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),%,175,97605,DB00977,Ethinyl Estradiol
,15722070,Cmax,"Similarly, vaginal administration of the levonorgestrel regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=15.2 ng/mL, p=.006) and a later Tmax (7.4 vs. 1.3 h, p=.037) for levonorgestel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),[ng] / [ml],5.4,97606,DB00977,Ethinyl Estradiol
,15722070,Cmax,"Similarly, vaginal administration of the levonorgestrel regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=15.2 ng/mL, p=.006) and a later Tmax (7.4 vs. 1.3 h, p=.037) for levonorgestel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),[ng] / [ml],15.2,97607,DB00977,Ethinyl Estradiol
,15722070,Tmax,"Similarly, vaginal administration of the levonorgestrel regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=15.2 ng/mL, p=.006) and a later Tmax (7.4 vs. 1.3 h, p=.037) for levonorgestel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),h,7.4,97608,DB00977,Ethinyl Estradiol
,15722070,Tmax,"Similarly, vaginal administration of the levonorgestrel regimen resulted in a lower Cmax (vaginal=5.4 vs. oral=15.2 ng/mL, p=.006) and a later Tmax (7.4 vs. 1.3 h, p=.037) for levonorgestel, compared to oral administration.",Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),h,1.3,97609,DB00977,Ethinyl Estradiol
,15722070,relative bioavailability,The relative bioavailability was 62%.,Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15722070/),%,62,97610,DB00977,Ethinyl Estradiol
,16981874,total apparent oral clearance,"Compared with the HC-free interval, HC intake was associated with a mean 21.5% increase in VPA total apparent oral clearance (from 8.0 +/- 5.2 to 9.7 +/- 6.4 ml/h/kg, p = 0.01) and a 45.2 % increase in VPA unbound apparent oral clearance (from 79 +/- 81 to 115 +/- 121 ml/h/kg, p = 0.029).",Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981874/),[ml] / [h·kg],8.0,99715,DB00977,Ethinyl Estradiol
,16981874,total apparent oral clearance,"Compared with the HC-free interval, HC intake was associated with a mean 21.5% increase in VPA total apparent oral clearance (from 8.0 +/- 5.2 to 9.7 +/- 6.4 ml/h/kg, p = 0.01) and a 45.2 % increase in VPA unbound apparent oral clearance (from 79 +/- 81 to 115 +/- 121 ml/h/kg, p = 0.029).",Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981874/),[ml] / [h·kg],9.7,99716,DB00977,Ethinyl Estradiol
,16981874,unbound apparent oral clearance,"Compared with the HC-free interval, HC intake was associated with a mean 21.5% increase in VPA total apparent oral clearance (from 8.0 +/- 5.2 to 9.7 +/- 6.4 ml/h/kg, p = 0.01) and a 45.2 % increase in VPA unbound apparent oral clearance (from 79 +/- 81 to 115 +/- 121 ml/h/kg, p = 0.029).",Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981874/),[ml] / [h·kg],79,99717,DB00977,Ethinyl Estradiol
,16981874,unbound apparent oral clearance,"Compared with the HC-free interval, HC intake was associated with a mean 21.5% increase in VPA total apparent oral clearance (from 8.0 +/- 5.2 to 9.7 +/- 6.4 ml/h/kg, p = 0.01) and a 45.2 % increase in VPA unbound apparent oral clearance (from 79 +/- 81 to 115 +/- 121 ml/h/kg, p = 0.029).",Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981874/),[ml] / [h·kg],115,99718,DB00977,Ethinyl Estradiol
,33785318,serum levels,"After a hypothetical 364 days of continuous CVS use, we predicted daily mean serum levels to be 184 pmol/L (95% confidence interval [CI], 102‒332 pmol/L) for SA and 43 pmol/L (95% CI, 19‒95 pmol/L) for EE.",Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33785318/),[pM] / [l],184,100501,DB00977,Ethinyl Estradiol
,33785318,serum levels,"After a hypothetical 364 days of continuous CVS use, we predicted daily mean serum levels to be 184 pmol/L (95% confidence interval [CI], 102‒332 pmol/L) for SA and 43 pmol/L (95% CI, 19‒95 pmol/L) for EE.",Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33785318/),[pM] / [l],43,100502,DB00977,Ethinyl Estradiol
,30500075,terminal half-life,The harmonic mean terminal half-life for ethinylestradiol (7.7 vs 7.0 hours) and levonorgestrel (37.1 vs 33.1 hours) was similar in the presence and absence of upadacitinib.,The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500075/),h,7.7,102678,DB00977,Ethinyl Estradiol
,30500075,terminal half-life,The harmonic mean terminal half-life for ethinylestradiol (7.7 vs 7.0 hours) and levonorgestrel (37.1 vs 33.1 hours) was similar in the presence and absence of upadacitinib.,The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500075/),h,7.0,102679,DB00977,Ethinyl Estradiol
,30500075,terminal half-life,The harmonic mean terminal half-life for ethinylestradiol (7.7 vs 7.0 hours) and levonorgestrel (37.1 vs 33.1 hours) was similar in the presence and absence of upadacitinib.,The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500075/),h,37.1,102680,DB00977,Ethinyl Estradiol
,30500075,terminal half-life,The harmonic mean terminal half-life for ethinylestradiol (7.7 vs 7.0 hours) and levonorgestrel (37.1 vs 33.1 hours) was similar in the presence and absence of upadacitinib.,The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30500075/),h,33.1,102681,DB00977,Ethinyl Estradiol
,16904418,Peak plasma concentrations,Peak plasma concentrations of CMA were approximately 1600 pg/mL after single-dose administration and 2000 pg/mL after multiple dosing.,Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),[pg] / [ml],1600,103339,DB00977,Ethinyl Estradiol
,16904418,Peak plasma concentrations,Peak plasma concentrations of CMA were approximately 1600 pg/mL after single-dose administration and 2000 pg/mL after multiple dosing.,Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),[pg] / [ml],2000,103340,DB00977,Ethinyl Estradiol
,16904418,constant trough,"CMA and EE showed linear pharmacokinetics throughout six cycles, with constant trough values of approximately 400-500 pg/mL for CMA and 20-40 pg/mL for EE.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),[pg] / [ml],400-500,103341,DB00977,Ethinyl Estradiol
,16904418,constant trough,"CMA and EE showed linear pharmacokinetics throughout six cycles, with constant trough values of approximately 400-500 pg/mL for CMA and 20-40 pg/mL for EE.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),[pg] / [ml],20-40,103342,DB00977,Ethinyl Estradiol
,16904418,Mass balance factors,"Mass balance factors were 1.2-1.4 for CMA and 1.6-1.7 for EE, and accumulation factors were 1.7-2 for CMA and 1.7-1.8 for EE.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),,1.2-1.4,103343,DB00977,Ethinyl Estradiol
,16904418,Mass balance factors,"Mass balance factors were 1.2-1.4 for CMA and 1.6-1.7 for EE, and accumulation factors were 1.7-2 for CMA and 1.7-1.8 for EE.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),,1.6-1.7,103344,DB00977,Ethinyl Estradiol
,16904418,accumulation factors,"Mass balance factors were 1.2-1.4 for CMA and 1.6-1.7 for EE, and accumulation factors were 1.7-2 for CMA and 1.7-1.8 for EE.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),,1.7-2,103345,DB00977,Ethinyl Estradiol
,16904418,accumulation factors,"Mass balance factors were 1.2-1.4 for CMA and 1.6-1.7 for EE, and accumulation factors were 1.7-2 for CMA and 1.7-1.8 for EE.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),,1.7-1.8,103346,DB00977,Ethinyl Estradiol
,16904418,"t(1/2,z)","Mean t(1/2,z) of CMA was approximately 25 h after single dosing and 36-39 h at steady state.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),h,25,103347,DB00977,Ethinyl Estradiol
,16904418,"t(1/2,z)","Mean t(1/2,z) of CMA was approximately 25 h after single dosing and 36-39 h at steady state.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),h,36-39,103348,DB00977,Ethinyl Estradiol
,16904418,"t(1/2,z)","The t(1/2,z) of CMA was 36-39 h after multiple dosing, which is considerably shorter than the 80 h often quoted in the literature.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),h,36-39,103349,DB00977,Ethinyl Estradiol
,16904418,"t(1/2,z)","The t(1/2,z) of CMA was 36-39 h after multiple dosing, which is considerably shorter than the 80 h often quoted in the literature.",Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16904418/),h,80,103350,DB00977,Ethinyl Estradiol
,2971509,peak levels,Highest serum concentrations were measured on Day 21 of the 3rd and 6th cycle with peak levels between 1.5 and 6.2 ng/ml.,Serum levels of 3-keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2971509/),[ng] / [ml],1.5 and 6.2,104934,DB00977,Ethinyl Estradiol
,8724621,alpha,"After compartmental analysis, the disposition of EE2 was well described by a two-compartmental open model with mean values of: alpha = 0.3448 +/- 0.2922, 0.1965 +/- 0.1755, 0.3058 +/- 0.1225 min-1, and beta = 0.0137 +/- 0.0018, 0.0140 +/- 0.0065, 0.0198 +/- 0.0066 min-1, for the three doses studied, respectively.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),1/[min],0.3448,106868,DB00977,Ethinyl Estradiol
,8724621,alpha,"After compartmental analysis, the disposition of EE2 was well described by a two-compartmental open model with mean values of: alpha = 0.3448 +/- 0.2922, 0.1965 +/- 0.1755, 0.3058 +/- 0.1225 min-1, and beta = 0.0137 +/- 0.0018, 0.0140 +/- 0.0065, 0.0198 +/- 0.0066 min-1, for the three doses studied, respectively.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),1/[min],0.1965,106869,DB00977,Ethinyl Estradiol
,8724621,alpha,"After compartmental analysis, the disposition of EE2 was well described by a two-compartmental open model with mean values of: alpha = 0.3448 +/- 0.2922, 0.1965 +/- 0.1755, 0.3058 +/- 0.1225 min-1, and beta = 0.0137 +/- 0.0018, 0.0140 +/- 0.0065, 0.0198 +/- 0.0066 min-1, for the three doses studied, respectively.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),1/[min],0.3058,106870,DB00977,Ethinyl Estradiol
,8724621,beta,"After compartmental analysis, the disposition of EE2 was well described by a two-compartmental open model with mean values of: alpha = 0.3448 +/- 0.2922, 0.1965 +/- 0.1755, 0.3058 +/- 0.1225 min-1, and beta = 0.0137 +/- 0.0018, 0.0140 +/- 0.0065, 0.0198 +/- 0.0066 min-1, for the three doses studied, respectively.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),1/[min],0.0137,106871,DB00977,Ethinyl Estradiol
,8724621,beta,"After compartmental analysis, the disposition of EE2 was well described by a two-compartmental open model with mean values of: alpha = 0.3448 +/- 0.2922, 0.1965 +/- 0.1755, 0.3058 +/- 0.1225 min-1, and beta = 0.0137 +/- 0.0018, 0.0140 +/- 0.0065, 0.0198 +/- 0.0066 min-1, for the three doses studied, respectively.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),1/[min],0.0140,106872,DB00977,Ethinyl Estradiol
,8724621,beta,"After compartmental analysis, the disposition of EE2 was well described by a two-compartmental open model with mean values of: alpha = 0.3448 +/- 0.2922, 0.1965 +/- 0.1755, 0.3058 +/- 0.1225 min-1, and beta = 0.0137 +/- 0.0018, 0.0140 +/- 0.0065, 0.0198 +/- 0.0066 min-1, for the three doses studied, respectively.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),1/[min],0.0198,106873,DB00977,Ethinyl Estradiol
,8724621,clearance,"There were no dose-related differences (ANOVA, P < 0.05) in a, b or Vss, but significant differences were detected in clearance (90.9 +/- 18.7; 80.6 +/- 17.6; 116.3 +/- 21.5 ml.min-1.kg-1) between the 100 micrograms.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),[ml] / [kg·min],90.9,106874,DB00977,Ethinyl Estradiol
,8724621,clearance,"There were no dose-related differences (ANOVA, P < 0.05) in a, b or Vss, but significant differences were detected in clearance (90.9 +/- 18.7; 80.6 +/- 17.6; 116.3 +/- 21.5 ml.min-1.kg-1) between the 100 micrograms.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),[ml] / [kg·min],80.6,106875,DB00977,Ethinyl Estradiol
,8724621,clearance,"There were no dose-related differences (ANOVA, P < 0.05) in a, b or Vss, but significant differences were detected in clearance (90.9 +/- 18.7; 80.6 +/- 17.6; 116.3 +/- 21.5 ml.min-1.kg-1) between the 100 micrograms.",Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),[ml] / [kg·min],116.3,106876,DB00977,Ethinyl Estradiol
,8724621,AUC,The AUC increased significantly with the doses (341.7 +/- 67.1; 645.8 +/- 143.9; 892.2 +/- 211.9 ng.min.ml-1).,Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),[min·ng] / [ml],341.7,106877,DB00977,Ethinyl Estradiol
,8724621,AUC,The AUC increased significantly with the doses (341.7 +/- 67.1; 645.8 +/- 143.9; 892.2 +/- 211.9 ng.min.ml-1).,Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),[min·ng] / [ml],645.8,106878,DB00977,Ethinyl Estradiol
,8724621,AUC,The AUC increased significantly with the doses (341.7 +/- 67.1; 645.8 +/- 143.9; 892.2 +/- 211.9 ng.min.ml-1).,Pharmacokinetics of ethinyloestradiol in rabbits after intravenous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8724621/),[min·ng] / [ml],892.2,106879,DB00977,Ethinyl Estradiol
,23153898,clearance,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),[l] / [h],0.52,111704,DB00977,Ethinyl Estradiol
,23153898,half-life,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),h,65,111705,DB00977,Ethinyl Estradiol
,23153898,area under the curve (AUC),"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),[h·ng] / [ml],232,111706,DB00977,Ethinyl Estradiol
,23153898,time to reach steady state,"Key LNG PK parameters were as follows: clearance, 0.52 L/h (SD 0.24); half-life, 65 h (SD 40); area under the curve (AUC), 232 h*ng/mL (SD 102); and time to reach steady state, 13.6 days (SD 8.4).",Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23153898/),d,13.6,111707,DB00977,Ethinyl Estradiol
,19773204,ch,The method had a chromatographic run time of 2.50 min and a linear calibration curve over the range 5-500 pg ml(-1) (r(2)>0.9992).,A novel and sensitive method for ethinylestradiol quantification in human plasma by high-performance liquid chromatography coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry: application to a comparative pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773204/),min,2.50,111739,DB00977,Ethinyl Estradiol
,19773204,run time,The method had a chromatographic run time of 2.50 min and a linear calibration curve over the range 5-500 pg ml(-1) (r(2)>0.9992).,A novel and sensitive method for ethinylestradiol quantification in human plasma by high-performance liquid chromatography coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry: application to a comparative pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773204/),min,2.50,111740,DB00977,Ethinyl Estradiol
,19773204,recovery,"The recovery of ethinylestradiol was determined as part of the assay validation process and was 73.1 and 79.0% for the concentrations 15 and 375 pg ml(-1), respectively.",A novel and sensitive method for ethinylestradiol quantification in human plasma by high-performance liquid chromatography coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry: application to a comparative pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773204/),%,73.1,111741,DB00977,Ethinyl Estradiol
,19773204,recovery,"The recovery of ethinylestradiol was determined as part of the assay validation process and was 73.1 and 79.0% for the concentrations 15 and 375 pg ml(-1), respectively.",A novel and sensitive method for ethinylestradiol quantification in human plasma by high-performance liquid chromatography coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry: application to a comparative pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773204/),%,79.0,111742,DB00977,Ethinyl Estradiol
,1823082,maximal EE levels,"In the steady state, the maximal EE levels were 75 +/- 34 pg/ml (20EE/DG) and 136 +/- 55 pg/ml (30EE/DG), and the AUC were 464 +/- 236 pg.h/ml and 840 +/- 492 pg.h/ml.",Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823082/),[pg] / [ml],75,112755,DB00977,Ethinyl Estradiol
,1823082,maximal EE levels,"In the steady state, the maximal EE levels were 75 +/- 34 pg/ml (20EE/DG) and 136 +/- 55 pg/ml (30EE/DG), and the AUC were 464 +/- 236 pg.h/ml and 840 +/- 492 pg.h/ml.",Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823082/),[pg] / [ml],136,112756,DB00977,Ethinyl Estradiol
,1823082,AUC,"In the steady state, the maximal EE levels were 75 +/- 34 pg/ml (20EE/DG) and 136 +/- 55 pg/ml (30EE/DG), and the AUC were 464 +/- 236 pg.h/ml and 840 +/- 492 pg.h/ml.",Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823082/),[h·pg] / [ml],464,112757,DB00977,Ethinyl Estradiol
,1823082,AUC,"In the steady state, the maximal EE levels were 75 +/- 34 pg/ml (20EE/DG) and 136 +/- 55 pg/ml (30EE/DG), and the AUC were 464 +/- 236 pg.h/ml and 840 +/- 492 pg.h/ml.",Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823082/),[h·pg] / [ml],840,112758,DB00977,Ethinyl Estradiol
,7705098,terminal half-life,"Following single dose administration, a mean terminal half-life of 22 h was observed for LNG.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),h,22,115032,DB00977,Ethinyl Estradiol
,7705098,total clearance,The total clearance was 1.0 ml x min-1 x kg-1 and the volume of distribution was 128 l.,Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],1.0,115033,DB00977,Ethinyl Estradiol
,7705098,volume of distribution,The total clearance was 1.0 ml x min-1 x kg-1 and the volume of distribution was 128 l.,Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),l,128,115034,DB00977,Ethinyl Estradiol
,7705098,total,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],0.5,115035,DB00977,Ethinyl Estradiol
,7705098,free clearance,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[ml] / [kg·min],50,115036,DB00977,Ethinyl Estradiol
,7705098,volume of distribution,"As compared to single dose administration, the following changes were observed for LNG at the end of treatment cycles one and three: reduced total (0.5 ml x min-1 x kg-1) and free clearance (50 ml x min-1 x kg-1) and a reduced volume of distribution (52 l).",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),l,52,115037,DB00977,Ethinyl Estradiol
,7705098,free fraction,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,1.4,115038,DB00977,Ethinyl Estradiol
,7705098,fractions bound,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,55.0,115039,DB00977,Ethinyl Estradiol
,7705098,fractions bound,"After single dose administration, the free fraction of LNG was 1.4% and the fractions bound to SHBG and albumin were 55.0% and 43.6%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,43.6,115040,DB00977,Ethinyl Estradiol
,7705098,free fraction,"At the end of cycle one, the free fraction was only 1.0% and the fractions bound to SHBG and albumin were 69.4% and 30.0%, respectively.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),%,1.0,115041,DB00977,Ethinyl Estradiol
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],331.2,115042,DB00977,Ethinyl Estradiol
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],369.6,115043,DB00977,Ethinyl Estradiol
,7705098,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 331.2 and 369.6 pg x ml-1 x h, respectively, which corresponds to an about 11-24% increase as compared to single dose administration, where an AUC(0-4h) value of 298.3 pg x ml-1 x h was found.",Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705098/),[h·pg] / [ml],298.3,115044,DB00977,Ethinyl Estradiol
,31758920,AUC(0-72h),"The mean relative, non-dose-corrected PK estimates after single-dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 543.5 ng*h/mL, 296.1 ng*h/mL and 27.3 ng/mL for DRSP alone, and 442.0 ng*h/mL, 264.7 ng*h/mL and 37.5 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[h·ng] / [ml],543.5,116417,DB00977,Ethinyl Estradiol
,31758920,AUC(0-24h),"The mean relative, non-dose-corrected PK estimates after single-dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 543.5 ng*h/mL, 296.1 ng*h/mL and 27.3 ng/mL for DRSP alone, and 442.0 ng*h/mL, 264.7 ng*h/mL and 37.5 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[h·ng] / [ml],296.1,116418,DB00977,Ethinyl Estradiol
,31758920,AUC(0-24h),"The mean relative, non-dose-corrected PK estimates after single-dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 543.5 ng*h/mL, 296.1 ng*h/mL and 27.3 ng/mL for DRSP alone, and 442.0 ng*h/mL, 264.7 ng*h/mL and 37.5 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[h·ng] / [ml],442.0,116419,DB00977,Ethinyl Estradiol
,31758920,AUC(0-24h),"The mean relative, non-dose-corrected PK estimates after single-dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 543.5 ng*h/mL, 296.1 ng*h/mL and 27.3 ng/mL for DRSP alone, and 442.0 ng*h/mL, 264.7 ng*h/mL and 37.5 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[h·ng] / [ml],264.7,116420,DB00977,Ethinyl Estradiol
,31758920,Cmax,"The mean relative, non-dose-corrected PK estimates after single-dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 543.5 ng*h/mL, 296.1 ng*h/mL and 27.3 ng/mL for DRSP alone, and 442.0 ng*h/mL, 264.7 ng*h/mL and 37.5 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[ng] / [ml],27.3,116421,DB00977,Ethinyl Estradiol
,31758920,Cmax,"The mean relative, non-dose-corrected PK estimates after single-dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 543.5 ng*h/mL, 296.1 ng*h/mL and 27.3 ng/mL for DRSP alone, and 442.0 ng*h/mL, 264.7 ng*h/mL and 37.5 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[ng] / [ml],37.5,116422,DB00977,Ethinyl Estradiol
,31758920,AUC(0-72h),"The mean relative, non-dose-corrected PK estimates after repeated dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 1066.8 ng*h/ml, 570.2 ng*h/mL and 41.0 ng/mL for DRSP alone, and 1394.5 ng*h/mL, 732.8 ng*h/mL and 61.4 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[h·ng] / [ml],1066.8,116423,DB00977,Ethinyl Estradiol
,31758920,AUC(0-24h),"The mean relative, non-dose-corrected PK estimates after repeated dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 1066.8 ng*h/ml, 570.2 ng*h/mL and 41.0 ng/mL for DRSP alone, and 1394.5 ng*h/mL, 732.8 ng*h/mL and 61.4 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[h·ng] / [ml],570.2,116424,DB00977,Ethinyl Estradiol
,31758920,AUC(0-24h),"The mean relative, non-dose-corrected PK estimates after repeated dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 1066.8 ng*h/ml, 570.2 ng*h/mL and 41.0 ng/mL for DRSP alone, and 1394.5 ng*h/mL, 732.8 ng*h/mL and 61.4 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[h·ng] / [ml],1394.5,116425,DB00977,Ethinyl Estradiol
,31758920,AUC(0-24h),"The mean relative, non-dose-corrected PK estimates after repeated dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 1066.8 ng*h/ml, 570.2 ng*h/mL and 41.0 ng/mL for DRSP alone, and 1394.5 ng*h/mL, 732.8 ng*h/mL and 61.4 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[h·ng] / [ml],732.8,116426,DB00977,Ethinyl Estradiol
,31758920,Cmax,"The mean relative, non-dose-corrected PK estimates after repeated dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 1066.8 ng*h/ml, 570.2 ng*h/mL and 41.0 ng/mL for DRSP alone, and 1394.5 ng*h/mL, 732.8 ng*h/mL and 61.4 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[ng] / [ml],41.0,116427,DB00977,Ethinyl Estradiol
,31758920,Cmax,"The mean relative, non-dose-corrected PK estimates after repeated dose administration for the endpoints AUC(0-72h), AUC(0-24h) and Cmax were 1066.8 ng*h/ml, 570.2 ng*h/mL and 41.0 ng/mL for DRSP alone, and 1394.5 ng*h/mL, 732.8 ng*h/mL and 61.4 ng/mL for the DRSP/EE combination; p < 0.001.",Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31758920/),[ng] / [ml],61.4,116428,DB00977,Ethinyl Estradiol
,3242167,half-lives,"However, previous studies in baboons have shown that the half-lives of the free and sulfoconjugated EE are similar (ranging from 8.8 to 11.2 h), which is not consistent with this hypothesis.",Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242167/),h,8.8 to 11.2,116807,DB00977,Ethinyl Estradiol
,3242167,t1/2 beta,"The t1/2 beta (mean 9.28 h) of the 17-sulfate after IV administration was almost identical in women and baboons, and similar to the t1/2 beta of free EE, confirming the previous observation.",Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242167/),h,9.28,116808,DB00977,Ethinyl Estradiol
,3242167,conversions,"Only 3.4% of IV and 11.4% of the orally administered 17-sulfate appeared in the blood as free EE; with the 3-sulfate, the conversions were 13.7 and 20.7%, respectively, suggesting that these sulfates are not important slow-release reservoirs.",Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242167/),%,13.7,116809,DB00977,Ethinyl Estradiol
,3242167,conversions,"Only 3.4% of IV and 11.4% of the orally administered 17-sulfate appeared in the blood as free EE; with the 3-sulfate, the conversions were 13.7 and 20.7%, respectively, suggesting that these sulfates are not important slow-release reservoirs.",Human pharmacokinetics of ethynyl estradiol 3-sulfate and 17-sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3242167/),%,20.7,116810,DB00977,Ethinyl Estradiol
,2105872,peak levels,The serum concentration-time profiles for the three formulations showed that the range of mean peak levels was 2.3-2.8 ng/ml for LNG and 116-159 pg/ml for EE2.,Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[ng] / [ml],2.3-2.8,119744,DB00977,Ethinyl Estradiol
,2105872,peak levels,The serum concentration-time profiles for the three formulations showed that the range of mean peak levels was 2.3-2.8 ng/ml for LNG and 116-159 pg/ml for EE2.,Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[pg] / [ml],116-159,119745,DB00977,Ethinyl Estradiol
,2105872,areas under the curves,The ranges of mean values calculated for the areas under the curves were 15-16 ng.hr/ml for LNG and 1053-1390 pg.hr/ml for EE2.,Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[h·ng] / [ml],15-16,119746,DB00977,Ethinyl Estradiol
,2105872,areas under the curves,The ranges of mean values calculated for the areas under the curves were 15-16 ng.hr/ml for LNG and 1053-1390 pg.hr/ml for EE2.,Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[h·pg] / [ml],1053-1390,119747,DB00977,Ethinyl Estradiol
,2105872,volume of distribution,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[l] / [kg],1.6-1.8,119748,DB00977,Ethinyl Estradiol
,2105872,volume of distribution,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[l] / [kg],7.7-9.1,119749,DB00977,Ethinyl Estradiol
,2105872,clearance,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[ml] / [h·kg],84-88,119750,DB00977,Ethinyl Estradiol
,2105872,clearance,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),[ml] / [h·kg],0.67-0.99,119751,DB00977,Ethinyl Estradiol
,2105872,half-life,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),h,13-15,119752,DB00977,Ethinyl Estradiol
,2105872,half-life,"The ranges of mean values calculated for other pharmacokinetic parameters were: volume of distribution: LNG--1.6-1.8 L/kg, EE2--7.7-9.1 L/kg; clearance: LNG--84-88 ml/hr/kg, EE2--0.67-0.99 ml/hr/kg; half-life: LNG--13-15 hr, EE2--7-12 hrs.",Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105872/),h,7-12,119753,DB00977,Ethinyl Estradiol
,30280353,z-average particle size,"In the current study, a CMA-based self-microemulsifying drug delivery system (SMEDDS) was developed using 32% ethyl oleate as an oil phase, 40% Tween-80 as a surfactant, and 12% Transcutol P combined with 16% PEG400 as a cosurfactant, resulting in spherical droplets with a z-average particle size of 38.92 nm and an average zeta potential of - 3.18 mv.",Enhanced Oral Bioavailability of Chlormadinone Acetate through a Self-Microemulsifying Drug Delivery System for a Potential Dose Reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30280353/),nm,38.92,120785,DB00977,Ethinyl Estradiol
,30280353,zeta potential,"In the current study, a CMA-based self-microemulsifying drug delivery system (SMEDDS) was developed using 32% ethyl oleate as an oil phase, 40% Tween-80 as a surfactant, and 12% Transcutol P combined with 16% PEG400 as a cosurfactant, resulting in spherical droplets with a z-average particle size of 38.92 nm and an average zeta potential of - 3.18 mv.",Enhanced Oral Bioavailability of Chlormadinone Acetate through a Self-Microemulsifying Drug Delivery System for a Potential Dose Reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30280353/),mv,- 3.18,120786,DB00977,Ethinyl Estradiol
,8533624,Cmax,"Single-dose Cmax of 65 pg/ml and AUC of 612 pg h ml(-1) increased by 40-60% during treatment cycles as a result of accumulation EE2 induced basal SHBG (102nmol/L) and CBG (42 microgram/ml) serum levels to about 220 nmol/L and 87 microgram/ml, respectively, at the end of treatment cycles 1 and 3.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[pg] / [ml],65,124506,DB00977,Ethinyl Estradiol
,8533624,AUC,"Single-dose Cmax of 65 pg/ml and AUC of 612 pg h ml(-1) increased by 40-60% during treatment cycles as a result of accumulation EE2 induced basal SHBG (102nmol/L) and CBG (42 microgram/ml) serum levels to about 220 nmol/L and 87 microgram/ml, respectively, at the end of treatment cycles 1 and 3.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[h·pg] / [ml],612,124507,DB00977,Ethinyl Estradiol
,8533624,Cmax,"Single-dose Cmax of 3.5 ng/ml and AUC 0-24 h of 22 ng h ml(-1) increased to steady-state levels of 8-8.7 ng/ml and 90-106 ng h ml(-1), respectively.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[ng] / [ml],3.5,124508,DB00977,Ethinyl Estradiol
,8533624,AUC 0-24 h,"Single-dose Cmax of 3.5 ng/ml and AUC 0-24 h of 22 ng h ml(-1) increased to steady-state levels of 8-8.7 ng/ml and 90-106 ng h ml(-1), respectively.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[h·ng] / [ml],22,124509,DB00977,Ethinyl Estradiol
,8533624,steady-state levels,"Single-dose Cmax of 3.5 ng/ml and AUC 0-24 h of 22 ng h ml(-1) increased to steady-state levels of 8-8.7 ng/ml and 90-106 ng h ml(-1), respectively.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[ng] / [ml],8-8.7,124510,DB00977,Ethinyl Estradiol
,8533624,steady-state levels,"Single-dose Cmax of 3.5 ng/ml and AUC 0-24 h of 22 ng h ml(-1) increased to steady-state levels of 8-8.7 ng/ml and 90-106 ng h ml(-1), respectively.",A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533624/),[h·ng] / [ml],90-106,124511,DB00977,Ethinyl Estradiol
,29637542,AUCss,"Based on published clinical data, an AUCss value of 1,000 pg/ml.h was selected as the threshold for breakthrough bleeding.",Risk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29637542/),[pg] / [h·ml],"1,000",125794,DB00977,Ethinyl Estradiol
,3621943,t1/2,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),h,7.6,126883,DB00977,Ethinyl Estradiol
,3621943,bioavailability,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),[ng] / [h·ml],53.6,126884,DB00977,Ethinyl Estradiol
,3621943,C max,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),[ng] / [ml],4.63,126885,DB00977,Ethinyl Estradiol
,3621943,clearance,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),[l] / [h],22.6,126886,DB00977,Ethinyl Estradiol
,3621943,Vd,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),,2361,126887,DB00977,Ethinyl Estradiol
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],306,127236,DB00977,Ethinyl Estradiol
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],172,127237,DB00977,Ethinyl Estradiol
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],136,127238,DB00977,Ethinyl Estradiol
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],258,127239,DB00977,Ethinyl Estradiol
,15823769,AUC over a 24-hour dosing interval (AUC(tau)),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·pg] / [ml],1139,127782,DB00977,Ethinyl Estradiol
,15823769,AUC over a 24-hour dosing interval (AUC(tau)),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·pg] / [ml],1143,127783,DB00977,Ethinyl Estradiol
,15823769,C(max),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[pg] / [ml],133,127784,DB00977,Ethinyl Estradiol
,15823769,C(max),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[pg] / [ml],141,127785,DB00977,Ethinyl Estradiol
,15823769,AUC(tau),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·ng] / [ml],140,127786,DB00977,Ethinyl Estradiol
,15823769,AUC(tau),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·ng] / [ml],159,127787,DB00977,Ethinyl Estradiol
,15823769,C(max),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[ng] / [ml],21,127788,DB00977,Ethinyl Estradiol
,15823769,C(max),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[ng] / [ml],23,127789,DB00977,Ethinyl Estradiol
,9186253,half-life,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),h,15.5,128388,DB00977,Ethinyl Estradiol
,9186253,half-life,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),h,14.1,128389,DB00977,Ethinyl Estradiol
,9186253,excretion,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[nM] / [d],488,128390,DB00977,Ethinyl Estradiol
,9186253,excretion,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[nM] / [d],470,128391,DB00977,Ethinyl Estradiol
,9186253,concentration ratio,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,6.8,128392,DB00977,Ethinyl Estradiol
,9186253,concentration ratio,"30 +/- 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 +/- 3.5 vs. 14.1 +/- 2.1 h), urinary 6-beta-hydroxycortisol excretion (488 +/- 164 vs. 470 +/- 228 nmol/ day), 6-beta-hydroxycortisol-to-cortisol concentration ratio (6.8 +/- 3.1 vs. 6.1 +/- 3.1) and serum gamma-glutamyltransferase activity (12 +/- 3 vs. 11 +/- 3 IU/L).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,6.1,128393,DB00977,Ethinyl Estradiol
,9186253,half-life,"No difference in pharmacokinetic parameters between VGB and placebo sessions were found for ethinyl estradiol (half-life, 12.5 +/- 3.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,12.5,128394,DB00977,Ethinyl Estradiol
,9186253,AUC,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[ng] / [h·l],874,128395,DB00977,Ethinyl Estradiol
,9186253,AUC,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[ng] / [h·l],939,128396,DB00977,Ethinyl Estradiol
,9186253,half-life,"13.9 +/- 3.2 h; AUC, 874 +/- 301 vs. 939 +/- 272 ng/ L/h) and levonorgestrel (half-life, 17.7 +/- 5.2 vs.","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),,17.7,128397,DB00977,Ethinyl Estradiol
,9186253,AUC,"23.1 +/- 9.8 h; AUC, 27.5 +/- 9.6 vs. 30.0 +/- 12.0 micrograms/L/h).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[μg] / [h·l],27.5,128398,DB00977,Ethinyl Estradiol
,9186253,AUC,"23.1 +/- 9.8 h; AUC, 27.5 +/- 9.6 vs. 30.0 +/- 12.0 micrograms/L/h).","A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9186253/),[μg] / [h·l],30.0,128399,DB00977,Ethinyl Estradiol
,1445484,Cmax,"During the first treatment cycle, mean values of Cmax, AUC(0-4h), and AUC(0-24h) amounted to 4.3 ng.",Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445484/),ng,4.3,129472,DB00977,Ethinyl Estradiol
,15289960,maximum serum concentration,"The profile for serum EE2 concentration was similar during UDCA (mean maximum serum concentration 177 pg/ml, SEM 59) and during placebo treatment (153 pg/ml, SEM 62), and mean area under the curve (AUC) was 1374 pg/h per ml (SEM 580) and 1320 pg/h per ml (SEM 551) during the two regimens, respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),[pg] / [ml],177,131153,DB00977,Ethinyl Estradiol
,15289960,maximum serum concentration,"The profile for serum EE2 concentration was similar during UDCA (mean maximum serum concentration 177 pg/ml, SEM 59) and during placebo treatment (153 pg/ml, SEM 62), and mean area under the curve (AUC) was 1374 pg/h per ml (SEM 580) and 1320 pg/h per ml (SEM 551) during the two regimens, respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),[pg] / [ml],153,131154,DB00977,Ethinyl Estradiol
,15289960,area under the curve (AUC),"The profile for serum EE2 concentration was similar during UDCA (mean maximum serum concentration 177 pg/ml, SEM 59) and during placebo treatment (153 pg/ml, SEM 62), and mean area under the curve (AUC) was 1374 pg/h per ml (SEM 580) and 1320 pg/h per ml (SEM 551) during the two regimens, respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),[pg] / [h·ml],1374,131155,DB00977,Ethinyl Estradiol
,15289960,area under the curve (AUC),"The profile for serum EE2 concentration was similar during UDCA (mean maximum serum concentration 177 pg/ml, SEM 59) and during placebo treatment (153 pg/ml, SEM 62), and mean area under the curve (AUC) was 1374 pg/h per ml (SEM 580) and 1320 pg/h per ml (SEM 551) during the two regimens, respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),[pg] / [h·ml],1320,131156,DB00977,Ethinyl Estradiol
,15289960,serum enrichment,"During UDCA treatment, serum enrichment with this bile acid and with the metabolite iso-UDCA was 29% (16%) and 3% (2%), respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),%,29,131157,DB00977,Ethinyl Estradiol
,15289960,serum enrichment,"During UDCA treatment, serum enrichment with this bile acid and with the metabolite iso-UDCA was 29% (16%) and 3% (2%), respectively.",Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289960/),%,3,131158,DB00977,Ethinyl Estradiol
,29403945,run time,A run time of 9.0 min for each sample made it possible to analyze a throughput of more than 100 samples per day.,High-sensitivity simultaneous liquid chromatography-tandem mass spectrometry assay of ethinyl estradiol and levonorgestrel in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403945/),min,9.0,132759,DB00977,Ethinyl Estradiol
,21692601,t(max),"Ethinyl oestradiol absorption was rapid (median t(max) approximately 1 hour), and was not affected by ticagrelor.",Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692601/),h,1,133521,DB00977,Ethinyl Estradiol
,1458892,terminal half-life,"At the end of treatment cycles one and three, the terminal half-life of LNG was in the range of 24-26 h, while a mean value of 20 h was observed following single dose administration.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),h,24-26,140073,DB00977,Ethinyl Estradiol
,1458892,terminal half-life,"At the end of treatment cycles one and three, the terminal half-life of LNG was in the range of 24-26 h, while a mean value of 20 h was observed following single dose administration.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),h,20,140074,DB00977,Ethinyl Estradiol
,1458892,free fraction,"After single dose administration, the free fraction of LNG was 1.3 +/- 0.2% and the fractions bound to SHBG and albumin were 64.1 +/- 4.2% and 34.6 +/- 4.0%, respectively.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),%,1.3,140075,DB00977,Ethinyl Estradiol
,1458892,fractions,"After single dose administration, the free fraction of LNG was 1.3 +/- 0.2% and the fractions bound to SHBG and albumin were 64.1 +/- 4.2% and 34.6 +/- 4.0%, respectively.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),%,64.1,140076,DB00977,Ethinyl Estradiol
,1458892,fractions,"After single dose administration, the free fraction of LNG was 1.3 +/- 0.2% and the fractions bound to SHBG and albumin were 64.1 +/- 4.2% and 34.6 +/- 4.0%, respectively.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),%,34.6,140077,DB00977,Ethinyl Estradiol
,1458892,AUC(0-24h),"On the last day of treatment cycles one and three, the AUC(0-24h) values of EE2 were 728 +/- 314 and 778 +/- 318 pg x ml-1 x h, respectively, and were in keeping with data reported from others.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),[h·pg] / [ml],728,140078,DB00977,Ethinyl Estradiol
,1458892,AUC(0-24h),"On the last day of treatment cycles one and three, the AUC(0-24h) values of EE2 were 728 +/- 314 and 778 +/- 318 pg x ml-1 x h, respectively, and were in keeping with data reported from others.","Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458892/),[h·pg] / [ml],778,140079,DB00977,Ethinyl Estradiol
,2058339,t1/2,"Deposiston was found markedly delay the elimination half-life life of caffeine (p less than 0.05): t1/2 prior to therapy 4.9 +/- 2.6 h and, after as little as 2 mg ethinylestradiol sulphonate 8.0 +/- 3.5 h.",[Time course of inhibition of caffeine elimination in response to the oral depot contraceptive agent Deposiston. Hormonal contraceptives and caffeine elimination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058339/),h,4.9,141771,DB00977,Ethinyl Estradiol
,2058339,t1/2,"Deposiston was found markedly delay the elimination half-life life of caffeine (p less than 0.05): t1/2 prior to therapy 4.9 +/- 2.6 h and, after as little as 2 mg ethinylestradiol sulphonate 8.0 +/- 3.5 h.",[Time course of inhibition of caffeine elimination in response to the oral depot contraceptive agent Deposiston. Hormonal contraceptives and caffeine elimination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058339/),h,8.0,141772,DB00977,Ethinyl Estradiol
,1905949,Tel,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,17.3,142225,DB00977,Ethinyl Estradiol
,1905949,Tel,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,16.4,142226,DB00977,Ethinyl Estradiol
,1905949,AUC,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),[ng] / [h·ml],11.1,142227,DB00977,Ethinyl Estradiol
,1905949,AUC,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,16.4,142228,DB00977,Ethinyl Estradiol
,1905949,AUC,"The pharmacokinetics of EE were not influenced by LNG; mean values for Tel and AUC were 17.3 +/- 5.5 h and 11.1 +/- 3.8 ng/ml/h, respectively, when EE was administered alone compared with 16.4 +/- 4.8 h and 12.5 +/- 3.9 ng/ml/h when given with LNG.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),[ng] / [h·ml],12.5,142229,DB00977,Ethinyl Estradiol
,1905949,Tel,"However, EE influenced the metabolism of LNG; Tel for LNG was 19.3 +/- 4.2 h when administered alone and significantly higher (30.0 +/- 11.2 h) when given with EE.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,19.3,142230,DB00977,Ethinyl Estradiol
,1905949,Tel,"However, EE influenced the metabolism of LNG; Tel for LNG was 19.3 +/- 4.2 h when administered alone and significantly higher (30.0 +/- 11.2 h) when given with EE.",Intrasubject variability in the pharmacokinetics of ethynyloestradiol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1905949/),h,30.0,142231,DB00977,Ethinyl Estradiol
,3127114,fractional bioavailability,The fractional bioavailability of LNG after oral administration was 1.00 +/- 0.16 (mean +/- S.D.) and after vaginal insertion 0.88 +/- 0.16.,"Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127114/),,1.00,144138,DB00977,Ethinyl Estradiol
,3127114,fractional bioavailability,The fractional bioavailability of LNG after oral administration was 1.00 +/- 0.16 (mean +/- S.D.) and after vaginal insertion 0.88 +/- 0.16.,"Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127114/),,0.88,144139,DB00977,Ethinyl Estradiol
,3127114,fractional bioavailability,"The fractional bioavailability of EE2 after oral dosing was 0.62 +/- 0.11 and after vaginal insertion 0.74 +/- 0.16; tmax was prolonged, hence absorption was slower from the vagina.","Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127114/),,0.62,144140,DB00977,Ethinyl Estradiol
,3127114,fractional bioavailability,"The fractional bioavailability of EE2 after oral dosing was 0.62 +/- 0.11 and after vaginal insertion 0.74 +/- 0.16; tmax was prolonged, hence absorption was slower from the vagina.","Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3127114/),,0.74,144141,DB00977,Ethinyl Estradiol
,20707071,flow rate,"Chromatographic separation was conducted on an C18 column (4.6 mm x 250 mm, 5 microm), using a mixture of methanol-water (75:25) as mobile phase at a flow rate of 1.0 mL min(-1) with UV detection at 289 nm, the column temperature was at 35 degrees C and ethinyl estradiol was used as an internal standard.",[Determination of indirubin in serum by HPLC and its application to pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20707071/),[ml] / [min],1.0,144559,DB00977,Ethinyl Estradiol
,20707071,limit of detection (LOD),The calibration curve for indirubin was linear ( R2 = 0.9996) in the range of 0.031-2.48 mg x L(-1) and the limit of detection (LOD) was 31 microg x L(-1).,[Determination of indirubin in serum by HPLC and its application to pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20707071/),[μg] / [l],31,144560,DB00977,Ethinyl Estradiol
more,20707071,recovery,The average recovery of indirubin in rat serum was more than 98% and the relative standard deviations of intra-day and inter-day were both less than 10%.,[Determination of indirubin in serum by HPLC and its application to pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20707071/),%,98,144561,DB00977,Ethinyl Estradiol
less,20707071,recovery,The average recovery of indirubin in rat serum was more than 98% and the relative standard deviations of intra-day and inter-day were both less than 10%.,[Determination of indirubin in serum by HPLC and its application to pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20707071/),%,10,144562,DB00977,Ethinyl Estradiol
,3121231,apparent clearance,The apparent clearance of levonorgestrel in group I was 80.9 +/- 15.6 ml/hr/kg and the half-life was 19.3 hours.,Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121231/),[ml] / [h·kg],80.9,147444,DB00977,Ethinyl Estradiol
,3121231,half-life,The apparent clearance of levonorgestrel in group I was 80.9 +/- 15.6 ml/hr/kg and the half-life was 19.3 hours.,Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121231/),h,19.3,147445,DB00977,Ethinyl Estradiol
,3121231,apparent oral clearance,The apparent oral clearance of ethinyl estradiol was 1002 +/- 398 ml/hr/kg in group I and the half-life averaged 7.7 hours.,Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121231/),[ml] / [h·kg],1002,147446,DB00977,Ethinyl Estradiol
,3121231,half-life,The apparent oral clearance of ethinyl estradiol was 1002 +/- 398 ml/hr/kg in group I and the half-life averaged 7.7 hours.,Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3121231/),h,7.7,147447,DB00977,Ethinyl Estradiol
exceeded,125164,Production rate (PR),"Production rate (PR) of testosterone exceeded 417 mug/24 h (1 SD above the mean reported for normal women), in nineteen of the twenty-five patients.",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],417,150467,DB00977,Ethinyl Estradiol
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],509,150468,DB00977,Ethinyl Estradiol
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],356,150469,DB00977,Ethinyl Estradiol
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],612,150470,DB00977,Ethinyl Estradiol
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],345,150471,DB00977,Ethinyl Estradiol
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],528,150472,DB00977,Ethinyl Estradiol
,125164,PR,"After 4 months, small dose betamethasone therapy (0.5 mg at bed time) had reduced the mean PR of testosterone in thirteen patients from 509 mug/24 h to 356 mug/24 h (P = 0.05); anovulatory steroids reduced mean PR of testosterone in nine from 612 mug/24 h to 345 mug/24 h (P less than 0.05, greater than 0.025), and the combination of both therapies in ten reduced PR of testosterone from 528 mug/24 h to 148 mug/24 h (P less than 0.001).",Chronic treatment regimens for hirsutism in women: effect on blood production rates of testosterone and on hair growth. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/125164/),[μg] / [24·h],148,150473,DB00977,Ethinyl Estradiol
,1445482,Maximum concentrations,Maximum concentrations of GEST were observed after 0.7 +/- 0.2 h and amounted to 4.9 +/- 2.4 ng/ml.,Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445482/),[ng] / [ml],4.9,160424,DB00977,Ethinyl Estradiol
,1445482,half lives,"A biphasic pattern of disposition was observed, with half lives of 0.13 +/- 0.06 h and 14.6 +/- 4.2 h, respectively.",Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445482/),h,0.13,160425,DB00977,Ethinyl Estradiol
,1445482,half lives,"A biphasic pattern of disposition was observed, with half lives of 0.13 +/- 0.06 h and 14.6 +/- 4.2 h, respectively.",Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445482/),h,14.6,160426,DB00977,Ethinyl Estradiol
,1445482,AUC,The AUC was 32.9 +/- 18.3 ng.ml-1.h.,Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445482/),[h·ng] / [ml],32.9,160427,DB00977,Ethinyl Estradiol
,1445482,maximum serum levels,"For KDG, maximum serum levels of 1.7 +/- 0.8 ng/ml were observed 1.5 +/- 0.8 h post administration.",Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445482/),[ng] / [ml],1.7,160428,DB00977,Ethinyl Estradiol
,1445482,half-lives,"Drug levels declined with half-lives of 0.5 +/- 0.2 h and 17.0 +/- 9.3 h, respectively, and the AUC was 15.2 +/- 10.9 ng.",Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445482/),h,0.5,160429,DB00977,Ethinyl Estradiol
,1445482,half-lives,"Drug levels declined with half-lives of 0.5 +/- 0.2 h and 17.0 +/- 9.3 h, respectively, and the AUC was 15.2 +/- 10.9 ng.",Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445482/),h,17.0,160430,DB00977,Ethinyl Estradiol
,1445482,AUC,"Drug levels declined with half-lives of 0.5 +/- 0.2 h and 17.0 +/- 9.3 h, respectively, and the AUC was 15.2 +/- 10.9 ng.",Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445482/),ng,15.2,160431,DB00977,Ethinyl Estradiol
,30963506,Cmax ratios,"Least-squares mean estimates (90% confidence interval) for Cmax ratios were 1.05 (0.90-1.23), 1.06 (0.97-1.16), and 1.04 (0.88-1.22) for norelgestromin, norgestrel, and ethinyl estradiol, respectively.","A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963506/),,1,161813,DB00977,Ethinyl Estradiol
,30963506,AUCtau ratios,"Respective AUCtau ratios were 1.02 (0.94-1.12), 1.03 (0.96-1.10), and 1.02 (0.91-1.14).","A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963506/),,1.02,161814,DB00977,Ethinyl Estradiol
,30963506,AUCtau ratios,"Respective AUCtau ratios were 1.02 (0.94-1.12), 1.03 (0.96-1.10), and 1.02 (0.91-1.14).","A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963506/),,1.03,161815,DB00977,Ethinyl Estradiol
,30963506,AUCtau ratios,"Respective AUCtau ratios were 1.02 (0.94-1.12), 1.03 (0.96-1.10), and 1.02 (0.91-1.14).","A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30963506/),,1.02,161816,DB00977,Ethinyl Estradiol
,7547095,Cmax,"Only the ethinyloestradiol Cmax showed a significant difference (P = 0.02) between menstrual cycles 1 and 2 (252.9 pg ml-1 and 271.3 pg ml-1, respectively).",An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547095/),[pg] / [ml],252.9,163192,DB00977,Ethinyl Estradiol
,7547095,Cmax,"Only the ethinyloestradiol Cmax showed a significant difference (P = 0.02) between menstrual cycles 1 and 2 (252.9 pg ml-1 and 271.3 pg ml-1, respectively).",An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547095/),[pg] / [ml],271.3,163193,DB00977,Ethinyl Estradiol
,6282871,clearance,"In keeping with these marked differences in tissue binding, the clearance of rLDL from the plasma equaled 847 +/- 36 microliters/h/100 g of rat while that of methyl-rLDL and hLDL was only 368 +/- 8 and 363 +/- 11 microliters/h/100 g of rat, respectively.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μl] / [100·g·h],847,168124,DB00977,Ethinyl Estradiol
,6282871,clearance,"In keeping with these marked differences in tissue binding, the clearance of rLDL from the plasma equaled 847 +/- 36 microliters/h/100 g of rat while that of methyl-rLDL and hLDL was only 368 +/- 8 and 363 +/- 11 microliters/h/100 g of rat, respectively.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μl] / [100·g·h],368,168125,DB00977,Ethinyl Estradiol
,6282871,clearance,"In keeping with these marked differences in tissue binding, the clearance of rLDL from the plasma equaled 847 +/- 36 microliters/h/100 g of rat while that of methyl-rLDL and hLDL was only 368 +/- 8 and 363 +/- 11 microliters/h/100 g of rat, respectively.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μl] / [100·g·h],363,168126,DB00977,Ethinyl Estradiol
,6282871,steady state plasma level,"When the steady state plasma level of rLDL was raised 2.5-fold, the clearance decreased slightly to 705 +/- 20 microliters/h/100 g of rat.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μl] / [100·h],705,168127,DB00977,Ethinyl Estradiol
,6282871,clearance,"When the steady state plasma level of rLDL was raised 2.5-fold, the clearance decreased slightly to 705 +/- 20 microliters/h/100 g of rat.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μl] / [100·h],705,168128,DB00977,Ethinyl Estradiol
,6282871,clearance,"The clearance of hLDL remained constant, however, at about 350 microliters/h/100 g of rat even when the plasma hLDL level was raised to very high values.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μl] / [100·g·h],350,168129,DB00977,Ethinyl Estradiol
,6282871,clearance,"The clearance of rHDL and hHDL equaled 644 +/- 16 and 408 +/- 13 microliters/h/100 g of rat, respectively, reflecting the more similar rate of binding of rHDL and hHDL to the tissues of the rat.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μl] / [100·g·h],644,168130,DB00977,Ethinyl Estradiol
,6282871,clearance,"The clearance of rHDL and hHDL equaled 644 +/- 16 and 408 +/- 13 microliters/h/100 g of rat, respectively, reflecting the more similar rate of binding of rHDL and hHDL to the tissues of the rat.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μl] / [100·g·h],408,168131,DB00977,Ethinyl Estradiol
,6282871,Rates,"Rates of whole animal sterol synthesis were lowered from 28 mumol/h to 8.8 mumol/h or 13 mumol/h by fasting and cholesterol feeding, respectively, and stimulated to 71 mumol/h by cholestyramine treatment.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μM] / [h],28,168132,DB00977,Ethinyl Estradiol
,6282871,Rates,"Rates of whole animal sterol synthesis were lowered from 28 mumol/h to 8.8 mumol/h or 13 mumol/h by fasting and cholesterol feeding, respectively, and stimulated to 71 mumol/h by cholestyramine treatment.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μM] / [h],8.8,168133,DB00977,Ethinyl Estradiol
,6282871,Rates,"Rates of whole animal sterol synthesis were lowered from 28 mumol/h to 8.8 mumol/h or 13 mumol/h by fasting and cholesterol feeding, respectively, and stimulated to 71 mumol/h by cholestyramine treatment.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μM] / [h],13,168134,DB00977,Ethinyl Estradiol
,6282871,Rates,"Rates of whole animal sterol synthesis were lowered from 28 mumol/h to 8.8 mumol/h or 13 mumol/h by fasting and cholesterol feeding, respectively, and stimulated to 71 mumol/h by cholestyramine treatment.",Correlation of low and high density lipoprotein binding in vivo with rates of lipoprotein degradation in the rat. A comparison of lipoproteins of rat and human origin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6282871/),[μM] / [h],71,168135,DB00977,Ethinyl Estradiol
,23944295,total T levels,With DHEA co-administration total T levels rise significantly (1.44 nmol/L with DHEA vs. 0.82 nmol/L with placebo; p < 0.001).,The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944295/),[nM] / [l],1.44,169553,DB00977,Ethinyl Estradiol
,23944295,total T levels,With DHEA co-administration total T levels rise significantly (1.44 nmol/L with DHEA vs. 0.82 nmol/L with placebo; p < 0.001).,The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23944295/),[nM] / [l],0.82,169554,DB00977,Ethinyl Estradiol
,6626419,clearance,"The combination of main effects tended to cancel one another (clearance of 49.1 ml h-1 kg-1 ideal body weight for OC non-user, non-smoker, vs 49.7 ml h-1 kg-1 for OC user-smoker).",Effects of tobacco smoking and oral contraceptive use on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626419/),[ml] / [h·kg],49.1,169892,DB00977,Ethinyl Estradiol
,6626419,clearance,"The combination of main effects tended to cancel one another (clearance of 49.1 ml h-1 kg-1 ideal body weight for OC non-user, non-smoker, vs 49.7 ml h-1 kg-1 for OC user-smoker).",Effects of tobacco smoking and oral contraceptive use on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626419/),[ml] / [h·kg],49.7,169893,DB00977,Ethinyl Estradiol
,20842042,AUC0-168 h,Patch EE median AUC0-168 h was 45% lower at 6010.36 pg·h·mL in those on LPV/r versus 10911.42 pg·h·mL in those on no HAART (P = 0.064).,Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·pg,6010.36,171328,DB00977,Ethinyl Estradiol
,20842042,AUC0-168 h,Patch EE median AUC0-168 h was 45% lower at 6010.36 pg·h·mL in those on LPV/r versus 10911.42 pg·h·mL in those on no HAART (P = 0.064).,Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·pg,10911.42,171329,DB00977,Ethinyl Estradiol
,20842042,AUC0-48 hours,Pill EE median AUC0-48 hours was similarly 55% lower at 344.67 pg·h·mL in those on LPV/r versus 765.38 pg·h·mL in those on no HAART (P = 0.003).,Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·pg,344.67,171330,DB00977,Ethinyl Estradiol
,20842042,AUC0-48 hours,Pill EE median AUC0-48 hours was similarly 55% lower at 344.67 pg·h·mL in those on LPV/r versus 765.38 pg·h·mL in those on no HAART (P = 0.003).,Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·pg,765.38,171331,DB00977,Ethinyl Estradiol
,20842042,AUC0-168 h,"Patch NGMN AUC0-168 h however, was 138.39 ng·h·mL, 83% higher in the LPV/r group compared with the control AUC of 75.63 ng·h·mL (P = 0.036).",Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·ng,138.39,171332,DB00977,Ethinyl Estradiol
,20842042,AUC,"Patch NGMN AUC0-168 h however, was 138.39 ng·h·mL, 83% higher in the LPV/r group compared with the control AUC of 75.63 ng·h·mL (P = 0.036).",Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·ng,75.63,171333,DB00977,Ethinyl Estradiol
,1301358,urinary to fecal excretion ratio,A urinary to fecal excretion ratio of 1.5 (i.v.) or 1.0 (i.g.) was found.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,1.5,171434,DB00977,Ethinyl Estradiol
,1301358,urinary to fecal excretion ratio,A urinary to fecal excretion ratio of 1.5 (i.v.) or 1.0 (i.g.) was found.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,1.0,171435,DB00977,Ethinyl Estradiol
,1301358,half-life,Renal excretion of total radiolabel proceeded with a half-life of about 0.8 (i.v.) or 1.1 (i.g.) days.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),d,0.8,171436,DB00977,Ethinyl Estradiol
,1301358,half-life,Renal excretion of total radiolabel proceeded with a half-life of about 0.8 (i.v.) or 1.1 (i.g.) days.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),d,1.1,171437,DB00977,Ethinyl Estradiol
,1301358,total clearance,Orally administered NETO was highly bioavailable (84.0 +/- 16.9% of dose) but rapidly cleared from plasma (total clearance corresponded to 97% of plasma liver flow).,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,97,171438,DB00977,Ethinyl Estradiol
,28285154,rate,"We observed an accumulation over the 12-week time at an estimated rate of 2.15 pg/mL per week (95% confidence interval 0.95-3.35, p<.001).",The pharmacokinetics of 12-week continuous contraceptive patch use. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28285154/),[pg] / [ml·week],2.15,171688,DB00977,Ethinyl Estradiol
,11763981,maximum DRSP concentrations,"The maximum DRSP concentrations (data given as mean +/- standard deviation) were reached on average 2.5+/-1.2 and 2.8+/-1.3 h in serum and breast milk, respectively after oral administration of 3 mg DRSP + 30 microg EE, and amounted on average to 30.8+/-14.4 and 13.5+/-11.7 ng DRSP/ml in serum and breast milk.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),h,2.5,172945,DB00977,Ethinyl Estradiol
,11763981,maximum DRSP concentrations,"The maximum DRSP concentrations (data given as mean +/- standard deviation) were reached on average 2.5+/-1.2 and 2.8+/-1.3 h in serum and breast milk, respectively after oral administration of 3 mg DRSP + 30 microg EE, and amounted on average to 30.8+/-14.4 and 13.5+/-11.7 ng DRSP/ml in serum and breast milk.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),h,2.8,172946,DB00977,Ethinyl Estradiol
,11763981,maximum DRSP concentrations,"The maximum DRSP concentrations (data given as mean +/- standard deviation) were reached on average 2.5+/-1.2 and 2.8+/-1.3 h in serum and breast milk, respectively after oral administration of 3 mg DRSP + 30 microg EE, and amounted on average to 30.8+/-14.4 and 13.5+/-11.7 ng DRSP/ml in serum and breast milk.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),[drsp·ng] / [ml],30.8,172947,DB00977,Ethinyl Estradiol
,11763981,maximum DRSP concentrations,"The maximum DRSP concentrations (data given as mean +/- standard deviation) were reached on average 2.5+/-1.2 and 2.8+/-1.3 h in serum and breast milk, respectively after oral administration of 3 mg DRSP + 30 microg EE, and amounted on average to 30.8+/-14.4 and 13.5+/-11.7 ng DRSP/ml in serum and breast milk.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),[drsp·ng] / [ml],13.5,172948,DB00977,Ethinyl Estradiol
,11763981,breast milk versus serum concentration ratios,The mean breast milk versus serum concentration ratios of DRSP increased from 0.16 to 0.57 within 2 h after dosing and decreased to 0.16 after 24 h.,Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),,0.16,172949,DB00977,Ethinyl Estradiol
,11763981,breast milk versus serum concentration ratios,The mean breast milk versus serum concentration ratios of DRSP increased from 0.16 to 0.57 within 2 h after dosing and decreased to 0.16 after 24 h.,Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),,0.57,172950,DB00977,Ethinyl Estradiol
,11763981,ratio of AUC0-48 h,"The average ratio of AUC0-48 h, values in breast milk versus serum was 0.23+/-0.09.",Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),,0.23,172951,DB00977,Ethinyl Estradiol
,11763981,concentration,The mean DRSP concentration in breast milk over the 24-h period after dosing was 3.7+/-1.9 ng/ml.,Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11763981/),[ng] / [ml],3.7,172952,DB00977,Ethinyl Estradiol
,3778555,initial half-lives,After intravenous administration disposition of unchanged drug in the plasma was biphasic with initial half-lives between 0.3 and 0.5 h and terminal half-lives between 2.3 and 3.0 h.,Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778555/),h,0.3 and 0.5,173899,DB00977,Ethinyl Estradiol
,3778555,terminal half-lives,After intravenous administration disposition of unchanged drug in the plasma was biphasic with initial half-lives between 0.3 and 0.5 h and terminal half-lives between 2.3 and 3.0 h.,Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778555/),h,2.3 and 3.0,173900,DB00977,Ethinyl Estradiol
,3778555,Systemic availability,"Systemic availability of intragastric EE2 amounted to 3% in the rat, 0.3% in the rabbit, 9% in the dog, 0.6% in rhesus monkeys and 2% in the baboon and was considerably lower than in humans (40%).",Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778555/),%,3,173901,DB00977,Ethinyl Estradiol
,3778555,Systemic availability,"Systemic availability of intragastric EE2 amounted to 3% in the rat, 0.3% in the rabbit, 9% in the dog, 0.6% in rhesus monkeys and 2% in the baboon and was considerably lower than in humans (40%).",Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778555/),%,0.3,173902,DB00977,Ethinyl Estradiol
,3778555,Systemic availability,"Systemic availability of intragastric EE2 amounted to 3% in the rat, 0.3% in the rabbit, 9% in the dog, 0.6% in rhesus monkeys and 2% in the baboon and was considerably lower than in humans (40%).",Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778555/),%,9,173903,DB00977,Ethinyl Estradiol
,3778555,Systemic availability,"Systemic availability of intragastric EE2 amounted to 3% in the rat, 0.3% in the rabbit, 9% in the dog, 0.6% in rhesus monkeys and 2% in the baboon and was considerably lower than in humans (40%).",Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778555/),%,0.6,173904,DB00977,Ethinyl Estradiol
,3778555,Systemic availability,"Systemic availability of intragastric EE2 amounted to 3% in the rat, 0.3% in the rabbit, 9% in the dog, 0.6% in rhesus monkeys and 2% in the baboon and was considerably lower than in humans (40%).",Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778555/),%,2,173905,DB00977,Ethinyl Estradiol
,3778555,Systemic availability,"Systemic availability of intragastric EE2 amounted to 3% in the rat, 0.3% in the rabbit, 9% in the dog, 0.6% in rhesus monkeys and 2% in the baboon and was considerably lower than in humans (40%).",Half-lives in plasma and bioavailability of ethinylestradiol in laboratory animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3778555/),%,40,173906,DB00977,Ethinyl Estradiol
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],867,174414,DB00977,Ethinyl Estradiol
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],795,174415,DB00977,Ethinyl Estradiol
,1830266,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) for oral EE2 alone was 867 +/- 338 pg/ml x h, for oral EE2 in the presence of gestodene it was 795 +/- 206 pg/ml x h and for oral EE2 in the presence of desogestrel it was 614 +/- 132 pg/ml x h.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[pg] / [h·ml],614,174416,DB00977,Ethinyl Estradiol
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,59.0,174417,DB00977,Ethinyl Estradiol
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,62.1,174418,DB00977,Ethinyl Estradiol
,1830266,bioavailability,"Comparing the relative oral and iv doses, the bioavailability of EE2 (alone) was 59.0 +/- 13% (n = 6), for EE2 plus gestodene it was 62.1 +/- 10% and for EE2 in the presence of desogestrel it was 62.1 +/- 4.4%.",The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),%,62.1,174419,DB00977,Ethinyl Estradiol
,1830266,clearance,The clearance of EE2 (alone) was 19.9 +/- 5.5 l/h and in the presence of gestodene it was 19.4 +/- 9.6 l/h.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],19.9,174420,DB00977,Ethinyl Estradiol
,1830266,clearance,The clearance of EE2 (alone) was 19.9 +/- 5.5 l/h and in the presence of gestodene it was 19.4 +/- 9.6 l/h.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],19.4,174421,DB00977,Ethinyl Estradiol
,1830266,clearance,The clearance of EE2 in the presence of desogestrel appeared slightly greater at 27.7 +/- 8.9 l/h but none of these clearance values were significantly different from each other.,The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1830266/),[l] / [h],27.7,174422,DB00977,Ethinyl Estradiol
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·pg] / [ml],1126,176226,DB00977,Ethinyl Estradiol
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·pg] / [ml],1208,176227,DB00977,Ethinyl Estradiol
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·ng] / [ml],178,176228,DB00977,Ethinyl Estradiol
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·ng] / [ml],171,176229,DB00977,Ethinyl Estradiol
,11020137,absolute bioavailability,"In comparison with the DSG/EE COC, the absolute bioavailability for NuvaRing was higher for etonogestrel (102.9 vs 79.2%) and similar for ethinylestradiol (55.6 vs 53.8%).",Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020137/),%,102.9,176230,DB00977,Ethinyl Estradiol
,11020137,absolute bioavailability,"In comparison with the DSG/EE COC, the absolute bioavailability for NuvaRing was higher for etonogestrel (102.9 vs 79.2%) and similar for ethinylestradiol (55.6 vs 53.8%).",Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020137/),%,79.2,176231,DB00977,Ethinyl Estradiol
,11020137,absolute bioavailability,"In comparison with the DSG/EE COC, the absolute bioavailability for NuvaRing was higher for etonogestrel (102.9 vs 79.2%) and similar for ethinylestradiol (55.6 vs 53.8%).",Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020137/),%,55.6,176232,DB00977,Ethinyl Estradiol
,11020137,absolute bioavailability,"In comparison with the DSG/EE COC, the absolute bioavailability for NuvaRing was higher for etonogestrel (102.9 vs 79.2%) and similar for ethinylestradiol (55.6 vs 53.8%).",Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020137/),%,53.8,176233,DB00977,Ethinyl Estradiol
,23160672,biocon,"The bioconcentration factors for E(2), EE(2), BPA, and NP were 217.9, 170.2, 382.3, and 289.1, respectively, suggesting that the estrogenic chemicals were concentrated in the embryo body through the jelly coat.",Accumulation and pharmacokinetics of estrogenic chemicals in the pre- and post-hatch embryos of the frog Rana rugosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23160672/),,217,176843,DB00977,Ethinyl Estradiol
,23160672,biocon,"The bioconcentration factors for E(2), EE(2), BPA, and NP were 217.9, 170.2, 382.3, and 289.1, respectively, suggesting that the estrogenic chemicals were concentrated in the embryo body through the jelly coat.",Accumulation and pharmacokinetics of estrogenic chemicals in the pre- and post-hatch embryos of the frog Rana rugosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23160672/),,170,176844,DB00977,Ethinyl Estradiol
,23160672,biocon,"The bioconcentration factors for E(2), EE(2), BPA, and NP were 217.9, 170.2, 382.3, and 289.1, respectively, suggesting that the estrogenic chemicals were concentrated in the embryo body through the jelly coat.",Accumulation and pharmacokinetics of estrogenic chemicals in the pre- and post-hatch embryos of the frog Rana rugosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23160672/),,382.3,176845,DB00977,Ethinyl Estradiol
,23160672,biocon,"The bioconcentration factors for E(2), EE(2), BPA, and NP were 217.9, 170.2, 382.3, and 289.1, respectively, suggesting that the estrogenic chemicals were concentrated in the embryo body through the jelly coat.",Accumulation and pharmacokinetics of estrogenic chemicals in the pre- and post-hatch embryos of the frog Rana rugosa. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23160672/),,289.1,176846,DB00977,Ethinyl Estradiol
,1543818,percentage conjugation,The percentage conjugation per mg dry weight for normal tissue (n = 11) was 17.1 +/- 6.4 (mean +/- s.d.) while in untreated coeliac tissue (n = 6) the figure was 6.3 +/- 3.6% (P less than 0.01).,The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1543818/),,17.1,177349,DB00977,Ethinyl Estradiol
,1543818,percentage conjugation,The percentage conjugation per mg dry weight for normal tissue (n = 11) was 17.1 +/- 6.4 (mean +/- s.d.) while in untreated coeliac tissue (n = 6) the figure was 6.3 +/- 3.6% (P less than 0.01).,The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1543818/),%,6.3,177350,DB00977,Ethinyl Estradiol
,28087972,area under the plasma concentration-time curve over the dosing interval of duration τ,"LNG alone for LNG area under the plasma concentration-time curve over the dosing interval of duration τ and maximum observed plasma concentration were 1.12 (1.07-1.18) and 1.05 (0.96-1.15), respectively.",Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087972/),,1.12,178605,DB00977,Ethinyl Estradiol
,28087972,maximum observed plasma concentration,"LNG alone for LNG area under the plasma concentration-time curve over the dosing interval of duration τ and maximum observed plasma concentration were 1.12 (1.07-1.18) and 1.05 (0.96-1.15), respectively.",Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28087972/),,1.05,178606,DB00977,Ethinyl Estradiol
,22727346,concentrations,"Mean day 0-21 EE(2) concentrations were lower among obese vs normal weight women (15.0 vs 22.0 pg/mL, respectively, P = .004), whereas etonorgestrel concentrations were similar (1138 vs 1256 pg/mL, respectively, P = .39).",Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727346/),[pg] / [ml],1138,179852,DB00977,Ethinyl Estradiol
,22727346,concentrations,"Mean day 0-21 EE(2) concentrations were lower among obese vs normal weight women (15.0 vs 22.0 pg/mL, respectively, P = .004), whereas etonorgestrel concentrations were similar (1138 vs 1256 pg/mL, respectively, P = .39).",Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727346/),[pg] / [ml],1256,179853,DB00977,Ethinyl Estradiol
below,1936077,t1/2,"Rat hepatocytes showed an extremely high metabolic activity towards NET, LN and GEST resulting in t1/2 values of below 2 min.",Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936077/),min,2,181047,DB00977,Ethinyl Estradiol
above,1936077,half-lives,"Respective values for rabbit hepatocytes ranged from 5-8 min, whereas half-lives calculated for liver cells from guinea pig, dog and monkey were generally above 30 min.",Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936077/),min,30,181048,DB00977,Ethinyl Estradiol
,8131397,maximum concentrations,"After single dose administration, maximum concentrations of CPA in the serum were 15.2 +/- 6.6 ng/ml.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[ng] / [ml],15.2,181084,DB00977,Ethinyl Estradiol
,8131397,half-lives,"Post maximum drug levels declined biphasically with half-lives of 0.8 +/- 0.4 h and 54.0 +/- 26.0 h, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),h,0.8,181085,DB00977,Ethinyl Estradiol
,8131397,half-lives,"Post maximum drug levels declined biphasically with half-lives of 0.8 +/- 0.4 h and 54.0 +/- 26.0 h, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),h,54.0,181086,DB00977,Ethinyl Estradiol
,8131397,apparent clearance,The apparent clearance was calculated to be 3.6 +/- 0.9 ml x min-1 x kg-1 and the volume of distribution (Vz) was 986 +/- 4371.,Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[ml] / [kg·min],3.6,181087,DB00977,Ethinyl Estradiol
,8131397,volume of distribution (Vz),The apparent clearance was calculated to be 3.6 +/- 0.9 ml x min-1 x kg-1 and the volume of distribution (Vz) was 986 +/- 4371.,Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),,986,181088,DB00977,Ethinyl Estradiol
,8131397,free fraction,"The free fraction of CPA was 3.5 +/- 1.9% and the fractions bound to heat labile proteins and albumin were 4.6 +/- 2.2% and 92.0 +/- 3.5%, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),%,3.5,181089,DB00977,Ethinyl Estradiol
,8131397,fractions,"The free fraction of CPA was 3.5 +/- 1.9% and the fractions bound to heat labile proteins and albumin were 4.6 +/- 2.2% and 92.0 +/- 3.5%, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),%,4.6,181090,DB00977,Ethinyl Estradiol
,8131397,fractions,"The free fraction of CPA was 3.5 +/- 1.9% and the fractions bound to heat labile proteins and albumin were 4.6 +/- 2.2% and 92.0 +/- 3.5%, respectively.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),%,92.0,181091,DB00977,Ethinyl Estradiol
,8131397,terminal half-life,"At the end of treatment cycle three, the terminal half-life of CPA had increased to a mean value of 78.6 +/- 16.0 h and the volume of distribution to a value of 1304 +/- 427 1.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),h,78.6,181092,DB00977,Ethinyl Estradiol
,8131397,volume of distribution,"At the end of treatment cycle three, the terminal half-life of CPA had increased to a mean value of 78.6 +/- 16.0 h and the volume of distribution to a value of 1304 +/- 427 1.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),1,1304,181093,DB00977,Ethinyl Estradiol
,8131397,apparent clearance,"The apparent clearance showed a small, although significant decrease to a value of 3.0 +/- 0.4 ml x min-1 x kg-1.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[ml] / [kg·min],3.0,181094,DB00977,Ethinyl Estradiol
,8131397,AUC(0-4h),The AUC(0-4h) values of EE2 following single dose administration of the combination oral contraceptive were found to be 187.5 +/- 79.7 pg x ml-1 x h.,Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[h·pg] / [ml],187.5,181095,DB00977,Ethinyl Estradiol
,8131397,AUC(0-4h),"On the last day of cycles one and three, the AUC(0-4h) values were 311.2 +/- 109.3 and 304.8 +/- 121.5 pg x ml-1 x h, respectively, which corresponds to an about 60% increase as compared to single dose administration.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[h·pg] / [ml],311.2,181096,DB00977,Ethinyl Estradiol
,8131397,AUC(0-4h),"On the last day of cycles one and three, the AUC(0-4h) values were 311.2 +/- 109.3 and 304.8 +/- 121.5 pg x ml-1 x h, respectively, which corresponds to an about 60% increase as compared to single dose administration.",Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8131397/),[h·pg] / [ml],304.8,181097,DB00977,Ethinyl Estradiol
,15504383,tmax,"When comparing the results obtained after the administration of EE/glucomannan dispersed in water with those obtained after the administration of this estrogen without fiber, we can see that Cmax is 1.4 times lower, AUC 1.9 times lower and that tmax is identical (10 min).",Effect of glucomannan and the dosage form on ethinylestradiol oral absorption in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15504383/),min,10,181854,DB00977,Ethinyl Estradiol
,29522253,maximum oral equivalent dose,"The maximum oral equivalent dose of ethinylestradiol was markedly lower than 30 μg ethinylestradiol per day (20.3 μg/day; 90% confidence interval, 14.8-28.0 μg/day).",In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522253/),[μg] / [d],20.3,183130,DB00977,Ethinyl Estradiol
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],"1,778",185596,DB00977,Ethinyl Estradiol
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],986,185597,DB00977,Ethinyl Estradiol
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],24.8,185598,DB00977,Ethinyl Estradiol
,21204827,area under the curve (AUC),"Mean area under the curve (AUC) measurements were lower during CBZ use compared to placebo for EE (1,778 vs. 986 pg*h/ml, p < 0.001) and LNG (24.8 vs. 13.8 pg*h/ml, p = 0.04).","Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21204827/),[h·pg] / [ml],13.8,185599,DB00977,Ethinyl Estradiol
,20472113,area under the curve (AUC,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[h·pg] / [ml],1077.2,188119,DB00977,Ethinyl Estradiol
,20472113,area under the curve (AUC,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[h·pg] / [ml],1413.7,188120,DB00977,Ethinyl Estradiol
,20472113,maximum values,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[pg] / [ml],85.7,188121,DB00977,Ethinyl Estradiol
,20472113,maximum values,"Obese women had a lower area under the curve (AUC; 1077.2 vs. 1413.7 pg*h/mL) and lower maximum values (85.7 vs. 129.5 pg/mL) for EE than normal-weight women (p=.04 and <0.01, respectively); EE trough levels were similar between BMI groups.",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[pg] / [ml],129.5,188122,DB00977,Ethinyl Estradiol
,20472113,trough levels,"While peak values differed somewhat, the LNG trough levels were similar for obese and normal-weight women (2.6 and 2.5 ng/mL, respectively).",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[ng] / [ml],2.6,188123,DB00977,Ethinyl Estradiol
,20472113,trough levels,"While peak values differed somewhat, the LNG trough levels were similar for obese and normal-weight women (2.6 and 2.5 ng/mL, respectively).",Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20472113/),[ng] / [ml],2.5,188124,DB00977,Ethinyl Estradiol
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],96,188806,DB00977,Ethinyl Estradiol
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],205,188807,DB00977,Ethinyl Estradiol
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],187,188808,DB00977,Ethinyl Estradiol
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],806,189197,DB00977,Ethinyl Estradiol
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],411,189198,DB00977,Ethinyl Estradiol
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],33.6,189199,DB00977,Ethinyl Estradiol
,2126946,AUC,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],19.5,189200,DB00977,Ethinyl Estradiol
,2126946,Ng,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],33.6,189201,DB00977,Ethinyl Estradiol
,2126946,Ng,Phenytoin reduced the AUC for EE2 from 806 +/- 50 (mean +/- s.d.) to 411 +/- 132 pg ml-1 h (P less than 0.05) and for Ng from 33.6 +/- 7.8 to 19.5 +/- 3.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],19.5,189202,DB00977,Ethinyl Estradiol
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],1163,189203,DB00977,Ethinyl Estradiol
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·pg] / [ml],672,189204,DB00977,Ethinyl Estradiol
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],22.9,189205,DB00977,Ethinyl Estradiol
,2126946,AUC,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],13.8,189206,DB00977,Ethinyl Estradiol
,2126946,Ng,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],22.9,189207,DB00977,Ethinyl Estradiol
,2126946,Ng,Carbamazepine reduced the AUC for EE2 from 1163 +/- 466 to 672 +/- 211 pg ml-1 h (P less than 0.05) and for Ng from 22.9 +/- 9.4 to 13.8 +/- 5.8 ng ml-1 h (P less than 0.05).,The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2126946/),[h·ng] / [ml],13.8,189208,DB00977,Ethinyl Estradiol
,30074167,T1/2,"T1/2 of plasma baicalin in the model group was significantly extended to (11.09±1.84) h, with clearance dropping to 61.78% of that of the normal control group (P<0.01).",Pharmacokinetic Characteristics of Baicalin in Rats with 17α-ethynyl-estradiol-induced Intrahepatic Cholestasis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30074167/),h,11.09,191231,DB00977,Ethinyl Estradiol
,4042465,distribution volume,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[l] / [kg],0.44,191767,DB00977,Ethinyl Estradiol
,4042465,distribution volume,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[l] / [kg],0.44,191768,DB00977,Ethinyl Estradiol
,4042465,total body clearance,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[ml] / [kg·min],0.78,191769,DB00977,Ethinyl Estradiol
,4042465,total body clearance,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[ml] / [kg·min],0.78,191770,DB00977,Ethinyl Estradiol
,4042465,elimination T 1/2,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),min,402,191771,DB00977,Ethinyl Estradiol
,4042465,elimination T 1/2,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),min,409,191772,DB00977,Ethinyl Estradiol
,26032952,C(max),"Median NES C(max) values for low, medium and high dose groups at day 21 were 318.6 pmol/L, 783.0 pmol/L and 1063.8 pmol/L, respectively.","A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032952/),[pM] / [l],318.6,197820,DB00977,Ethinyl Estradiol
,26032952,C(max),"Median NES C(max) values for low, medium and high dose groups at day 21 were 318.6 pmol/L, 783.0 pmol/L and 1063.8 pmol/L, respectively.","A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032952/),[pM] / [l],783.0,197821,DB00977,Ethinyl Estradiol
,26032952,C(max),"Median NES C(max) values for low, medium and high dose groups at day 21 were 318.6 pmol/L, 783.0 pmol/L and 1063.8 pmol/L, respectively.","A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032952/),[pM] / [l],1063.8,197822,DB00977,Ethinyl Estradiol
,26032952,maximum follicular diameter,"Median maximum follicular diameter was higher with the lowest dose with 16.2 mm versus 10.0 and 10.4 mm with the medium and high doses, respectively.","A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032952/),mm,16.2,197823,DB00977,Ethinyl Estradiol
,26032952,maximum follicular diameter,"Median maximum follicular diameter was higher with the lowest dose with 16.2 mm versus 10.0 and 10.4 mm with the medium and high doses, respectively.","A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032952/),mm,10.0,197824,DB00977,Ethinyl Estradiol
,26032952,maximum follicular diameter,"Median maximum follicular diameter was higher with the lowest dose with 16.2 mm versus 10.0 and 10.4 mm with the medium and high doses, respectively.","A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26032952/),mm,10.4,197825,DB00977,Ethinyl Estradiol
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],336,200510,DB00977,Ethinyl Estradiol
,5103749,metabolic clearance rate,"The mean dihydrotestosterone metabolic clearance rate was higher in men (336 liters/24 hr per m(2) [range, 239-448]) than in women (153 liters/24 hr per m(2) [range, 108-184]).",The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5-alpha-androstanediols. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5103749/),[24·h·l] / [m(2],153,200511,DB00977,Ethinyl Estradiol
,577076,half-life of the second phase,The half-life of the second phase was 7.5+/-1.7 (SD) hours.,Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577076/),h,7.5,200712,DB00977,Ethinyl Estradiol
,577076,half-life,Administration of rifampicin (600 mg for 6 days) shifted the half-life of ethinyloestradiol to 3.3+/-0.9 h while the apparent volume of distribution for the second phase of elimination was not changed.,Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577076/),h,3.3,200713,DB00977,Ethinyl Estradiol
,25385099,t1/2 (terminal half-life in plasma at steady state,Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2.4 h longer) and LNG (4.7 h longer) when EE and LNG were coadministered with faldaprevir.,Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385099/),h,2.4,203683,DB00977,Ethinyl Estradiol
,25385099,t1/2 (terminal half-life in plasma at steady state,Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2.4 h longer) and LNG (4.7 h longer) when EE and LNG were coadministered with faldaprevir.,Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25385099/),h,4.7,203684,DB00977,Ethinyl Estradiol
,29336615,Cmax0-24h ratio,"During the first day of use a burst effect was observed with Nuvaring®, with significantly higher level of ethinylestradiol (Cmax0-24h ratio: 78.34%, 94.12CI: 73.55-83.45%).","Pharmacokinetic bioequivalence, safety and acceptability of Ornibel®, a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29336615/),%,78.,205034,DB00977,Ethinyl Estradiol
,23360419,AUC,"The AUC of ethinylestradiol alone versus together with lacosamide was 1,067 ± 404 versus 1,173 ± 330 pg h/ml.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·pg] / [ml],"1,067",208129,DB00977,Ethinyl Estradiol
,23360419,AUC,"The AUC of ethinylestradiol alone versus together with lacosamide was 1,067 ± 404 versus 1,173 ± 330 pg h/ml.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·pg] / [ml],"1,173",208130,DB00977,Ethinyl Estradiol
,23360419,Cmax,Corresponding values of Cmax were 116.9 ± 48.8 versus 135.7 ± 28.6 pg/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[pg] / [ml],116.9,208131,DB00977,Ethinyl Estradiol
,23360419,Cmax,Corresponding values of Cmax were 116.9 ± 48.8 versus 135.7 ± 28.6 pg/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[pg] / [ml],135.7,208132,DB00977,Ethinyl Estradiol
,23360419,AUC,"For levonorgestrel, the AUC alone was 74.2 ± 21.4 versus 80.9 ± 18.5 ng h/ml with lacosamide.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·ng] / [ml],74.2,208133,DB00977,Ethinyl Estradiol
,23360419,AUC,"For levonorgestrel, the AUC alone was 74.2 ± 21.4 versus 80.9 ± 18.5 ng h/ml with lacosamide.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·ng] / [ml],80.9,208134,DB00977,Ethinyl Estradiol
,23360419,Cmax,Corresponding values of Cmax were 6.7 ± 1.9 versus 7.4 ± 1.5 ng/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[ng] / [ml],6.7,208135,DB00977,Ethinyl Estradiol
,23360419,Cmax,Corresponding values of Cmax were 6.7 ± 1.9 versus 7.4 ± 1.5 ng/ml.,Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[ng] / [ml],7.4,208136,DB00977,Ethinyl Estradiol
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.5,208137,DB00977,Ethinyl Estradiol
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.4,208138,DB00977,Ethinyl Estradiol
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.5,208139,DB00977,Ethinyl Estradiol
,23360419,tmax,"The AUC and Cmax point estimates and almost all 90% confidence intervals (except for Cmax of ethinylestradiol) for ethinylestradiol and levonorgestrel (with and without lacosamide) were within the conventional bioequivalence range, and no relevant changes in tmax were observed for ethinylestradiol (1.5 ± 0.6 h alone vs. 1.4 ± 0.7 h with lacosamide) or for levonorgestrel (1.5 ± 1.0 h alone vs. 1.1 ± 0.6 h with lacosamide).",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.1,208140,DB00977,Ethinyl Estradiol
,23360419,AUC,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[h·μg] / [ml],113.5,208141,DB00977,Ethinyl Estradiol
,23360419,Cmax,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),[μg] / [ml],13.8,208142,DB00977,Ethinyl Estradiol
,23360419,tmax,"Lacosamide pharmacokinetics were consistent with those observed in previous studies of lacosamide alone, with values for AUC of 113.5 ± 20.7 μg h/ml, Cmax of 13.8 ± 2.2 μg/ml, and tmax of 1.1 ± 0.4 h.",Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23360419/),h,1.1,208143,DB00977,Ethinyl Estradiol
,18279686,relative bioavailability,"The relative bioavailability of EE and drsp after EE-betadex clathrate/drsp tablet administration was comparable with that achieved with the EE/drsp tablet (107% and 101%, respectively).",Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18279686/),%,107,208933,DB00977,Ethinyl Estradiol
,18279686,relative bioavailability,"The relative bioavailability of EE and drsp after EE-betadex clathrate/drsp tablet administration was comparable with that achieved with the EE/drsp tablet (107% and 101%, respectively).",Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18279686/),%,101,208934,DB00977,Ethinyl Estradiol
,3082591,bioavailability,The mean bioavailability of ethinyloestradiol in the patients with an ileostomy was 55.4 +/- 10.9% (+/- S.D.) compared to a control value of 45.0 +/- 6.1% (p greater than or equal to 0.1).,The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082591/),%,55.4,208972,DB00977,Ethinyl Estradiol
,3082591,bioavailability,The mean bioavailability of ethinyloestradiol in the patients with an ileostomy was 55.4 +/- 10.9% (+/- S.D.) compared to a control value of 45.0 +/- 6.1% (p greater than or equal to 0.1).,The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082591/),%,45.0,208973,DB00977,Ethinyl Estradiol
,3082591,bioavailability,The mean bioavailability of levonorgestrel in the ileostomy patients was 85.2 +/- 13.1% compared to 104.6 +/- 22.3% in the controls (p greater than or equal to 0.1).,The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082591/),%,85.2,208974,DB00977,Ethinyl Estradiol
,3082591,bioavailability,The mean bioavailability of levonorgestrel in the ileostomy patients was 85.2 +/- 13.1% compared to 104.6 +/- 22.3% in the controls (p greater than or equal to 0.1).,The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082591/),%,104.6,208975,DB00977,Ethinyl Estradiol
,25070547,time to reach steady state,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),d,12,213784,DB00977,Ethinyl Estradiol
,25070547,Cmax,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[ng] / [ml],3.82,213785,DB00977,Ethinyl Estradiol
,25070547,Cmax,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[ng] / [ml],3.13,213786,DB00977,Ethinyl Estradiol
,25070547,AUC0-∞,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[h·ng] / [ml],267,213787,DB00977,Ethinyl Estradiol
,25070547,AUC0-∞,"At baseline, the key LNG PK parameters were no different between groups; average time to reach steady state was 12 days in both groups; Cmax were CC: 3.82±1.28 ng/mL and ID: 3.13±0.87 ng/mL; and AUC0-∞ were CC: 267±115 h ng/mL and ID: 199±75 h ng/mL.",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[h·ng] / [ml],199,213788,DB00977,Ethinyl Estradiol
,25070547,AUC,"However, AUC was not significantly different between CC (412±255 h ng/mL) and ID (283±130 h ng/mL).",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[h·ng] / [ml],412,213789,DB00977,Ethinyl Estradiol
,25070547,AUC,"However, AUC was not significantly different between CC (412±255 h ng/mL) and ID (283±130 h ng/mL).",Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25070547/),[h·ng] / [ml],283,213790,DB00977,Ethinyl Estradiol
,7189454,area under the plasma EE versus time curve,The area under the plasma EE versus time curve increased significantly on stopping rifampicin from 1014 +/- 317 pg/ml x h (mean +/- SE) to 1747 +/- 218 pg/ml x h (p less than 0.01).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),[pg] / [h·ml],1014,214896,DB00977,Ethinyl Estradiol
,7189454,area under the plasma EE versus time curve,The area under the plasma EE versus time curve increased significantly on stopping rifampicin from 1014 +/- 317 pg/ml x h (mean +/- SE) to 1747 +/- 218 pg/ml x h (p less than 0.01).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),[pg] / [h·ml],1747,214897,DB00977,Ethinyl Estradiol
,7189454,terminal plasma half-life,The terminal plasma half-life increased from 2.9 +/- 0.8 h to 6.3 +/- 1.4 h (p less than 0.005).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),h,2.9,214898,DB00977,Ethinyl Estradiol
,7189454,terminal plasma half-life,The terminal plasma half-life increased from 2.9 +/- 0.8 h to 6.3 +/- 1.4 h (p less than 0.005).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),h,6.3,214899,DB00977,Ethinyl Estradiol
,7189454,capacity,The sex hormone binding globulin (S.H.B.G.) capacity was also reduced from 213.4 +/- 11.5 nmoles to 129.0 +/- 7.7 nmoles/1 after stopping rifampicin.,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),nmoles,213.4,214900,DB00977,Ethinyl Estradiol
,7189454,capacity,The sex hormone binding globulin (S.H.B.G.) capacity was also reduced from 213.4 +/- 11.5 nmoles to 129.0 +/- 7.7 nmoles/1 after stopping rifampicin.,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),nmoles,129.0,214901,DB00977,Ethinyl Estradiol
,19631786,half-life,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),h,52.1,218919,DB00977,Ethinyl Estradiol
,19631786,half-life,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),h,25.6,218920,DB00977,Ethinyl Estradiol
,19631786,maximum LNG concentration,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),[ng] / [ml],1.9,218921,DB00977,Ethinyl Estradiol
,19631786,maximum LNG concentration,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),[ng] / [ml],2.5,218922,DB00977,Ethinyl Estradiol
,19631786,time to reach steady state,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),d,10,218923,DB00977,Ethinyl Estradiol
,19631786,time to reach steady state,"The LNG half-life was significantly longer in the obese group (52.1+/-29.4 vs. 25.6+/-9.3 h, p<.05), which correlated with a lower maximum LNG concentration on Cycle 2, Day 1 [1.9 ng/mL (SD, 0.5) vs. 2.5 ng/mL (SD, 0.7)] and a longer time to reach steady state (10 vs. 5 days) in obese women.",Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19631786/),d,5,218924,DB00977,Ethinyl Estradiol
,2150632,plateau levels,"Mean plateau levels (+/- s.d.) of 3-keto-desogestrel were 2.3 +/- 0.9, 2.8 +/- 1.1 and 3.8 +/- 1.1 pmol/ml for CVR 75/15, 100/15 and 150/15, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [ml],2.3,219693,DB00977,Ethinyl Estradiol
,2150632,plateau levels,"Mean plateau levels (+/- s.d.) of 3-keto-desogestrel were 2.3 +/- 0.9, 2.8 +/- 1.1 and 3.8 +/- 1.1 pmol/ml for CVR 75/15, 100/15 and 150/15, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [ml],2.8,219694,DB00977,Ethinyl Estradiol
,2150632,plateau levels,"Mean plateau levels (+/- s.d.) of 3-keto-desogestrel were 2.3 +/- 0.9, 2.8 +/- 1.1 and 3.8 +/- 1.1 pmol/ml for CVR 75/15, 100/15 and 150/15, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [ml],3.8,219695,DB00977,Ethinyl Estradiol
,2150632,plateau levels,"Mean plateau levels of ethinylestradiol were 184 +/- 75, 262 +/- 102 and 233 +/- 102 pmol/l, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [l],184,219696,DB00977,Ethinyl Estradiol
,2150632,plateau levels,"Mean plateau levels of ethinylestradiol were 184 +/- 75, 262 +/- 102 and 233 +/- 102 pmol/l, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [l],262,219697,DB00977,Ethinyl Estradiol
,2150632,plateau levels,"Mean plateau levels of ethinylestradiol were 184 +/- 75, 262 +/- 102 and 233 +/- 102 pmol/l, respectively.",Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2150632/),[pM] / [l],233,219698,DB00977,Ethinyl Estradiol
,3208516,maximal gestodene levels,During the 1st cycle the maximal gestodene levels increased from 2.1 to 6.2 ng/ml on Day 1 to values between 7.5 and 22.0 ng/ml on Day 21.,Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208516/),[ng] / [ml],2.1 to 6.2,221502,DB00977,Ethinyl Estradiol
,3208516,maximal gestodene levels,During the 1st cycle the maximal gestodene levels increased from 2.1 to 6.2 ng/ml on Day 1 to values between 7.5 and 22.0 ng/ml on Day 21.,Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208516/),[ng] / [ml],7.5 and 22.0,221503,DB00977,Ethinyl Estradiol
,3208516,maxima,"During the 3rd and 6th treatment cycle the levels were still higher with maxima between 10.1 and 26.3 ng/ml, while during the 12th cycle the gestodene concentrations were slightly lower.",Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3208516/),[ng] / [ml],10.1 and 26.3,221504,DB00977,Ethinyl Estradiol
,8222659,terminal half-life,"Following single dose administration, a mean terminal half-life of 18 h was observed for GEST.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),h,18,222309,DB00977,Ethinyl Estradiol
,8222659,total clearance,The total clearance was 0.9 ml x min-1 x kg-1 and the volume of distribution was 84 l.,Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],0.9,222310,DB00977,Ethinyl Estradiol
,8222659,volume of distribution,The total clearance was 0.9 ml x min-1 x kg-1 and the volume of distribution was 84 l.,Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),l,84,222311,DB00977,Ethinyl Estradiol
,8222659,terminal half-life,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),h,20 to 22,222312,DB00977,Ethinyl Estradiol
,8222659,total,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],0.16,222313,DB00977,Ethinyl Estradiol
,8222659,free clearance,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[ml] / [kg·min],27,222314,DB00977,Ethinyl Estradiol
,8222659,volume of distribution,"As compared to single dose administration, the following changes were observed for GEST at the end of treatment cycles one and three: prolonged terminal half-life (20 to 22 h), reduced total (0.16 ml x min-1 x kg-1) and free clearance (ca. 27 ml x min-1 x kg-1), reduced volume of distribution (ca. 18 l).",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),l,18,222315,DB00977,Ethinyl Estradiol
,8222659,free fraction,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,1.3,222316,DB00977,Ethinyl Estradiol
,8222659,fractions,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,69.4,222317,DB00977,Ethinyl Estradiol
,8222659,fractions,"After single dose administration, the free fraction of GEST was 1.3% and the fractions bound to SHBG and albumin were 69.4% and 29.3%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,29.3,222318,DB00977,Ethinyl Estradiol
,8222659,free fraction,"At the end of cycle one, the free fraction was only 0.6% and the fractions bound to SHBG and albumin were 81.4% and 18.0%, respectively.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),%,0.6,222319,DB00977,Ethinyl Estradiol
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],299.2,222320,DB00977,Ethinyl Estradiol
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],278.1,222321,DB00977,Ethinyl Estradiol
,8222659,AUC(0-4h),"On the last day of treatment cycles one and three, the AUC(0-4h) values of EE2 were 299.2 and 278.1 pg x ml-1 x h, respectively, which corresponds to an about 30% increase as compared to single dose administration, where an AUC(0-4h) value of 216.1 pg x ml-1 x h was found.",Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222659/),[h·pg] / [ml],216.1,222322,DB00977,Ethinyl Estradiol
,2959449,Bioavailability,Bioavailability ranged between 40.0 and 113% with a mean value ( +/- SD) of 76.1 +/- 22.5%.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),%,40.0 and 113,226075,DB00977,Ethinyl Estradiol
,2959449,Bioavailability,Bioavailability ranged between 40.0 and 113% with a mean value ( +/- SD) of 76.1 +/- 22.5%.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),%,76.1,226076,DB00977,Ethinyl Estradiol
less,2959449,bioavailability,Only 3 subjects had a bioavailability of less than 70%.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),%,70,226077,DB00977,Ethinyl Estradiol
,2959449,elimination half life,There was no significant difference in the elimination half life of 3-keto-desogestrel which was 12.6 +/- 4.1h following i.v. administration and 11.9 +/- 4.1h after oral administration of desogestrel.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),h,12.6,226078,DB00977,Ethinyl Estradiol
,2959449,elimination half life,There was no significant difference in the elimination half life of 3-keto-desogestrel which was 12.6 +/- 4.1h following i.v. administration and 11.9 +/- 4.1h after oral administration of desogestrel.,Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959449/),h,11.9,226079,DB00977,Ethinyl Estradiol
,18370508,relative bioavailabilities,"The results of these studies demonstrated that the mean relative bioavailabilities of DSG (measured as 3-keto-DSG, the active metabolite of DSG) and EE from the combination tablet were 100% and 93%, respectively, and that of EE from the EE tablet was 99%.",The bioavailability of desogestrel/ethinyl estradiol tablets relative to the oral solution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370508/),%,100,226132,DB00977,Ethinyl Estradiol
,18370508,relative bioavailabilities,"The results of these studies demonstrated that the mean relative bioavailabilities of DSG (measured as 3-keto-DSG, the active metabolite of DSG) and EE from the combination tablet were 100% and 93%, respectively, and that of EE from the EE tablet was 99%.",The bioavailability of desogestrel/ethinyl estradiol tablets relative to the oral solution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370508/),%,93,226133,DB00977,Ethinyl Estradiol
,18370508,relative bioavailabilities,"The results of these studies demonstrated that the mean relative bioavailabilities of DSG (measured as 3-keto-DSG, the active metabolite of DSG) and EE from the combination tablet were 100% and 93%, respectively, and that of EE from the EE tablet was 99%.",The bioavailability of desogestrel/ethinyl estradiol tablets relative to the oral solution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370508/),%,99,226134,DB00977,Ethinyl Estradiol
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,99.94,226877,DB00977,Ethinyl Estradiol
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,69.99,226878,DB00977,Ethinyl Estradiol
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,92.69,226879,DB00977,Ethinyl Estradiol
,22018130,percentage cumulative release,"The percentage cumulative release of F6 (optimized formulation) named as 'AGARPRU' was found to be 99.94%±1.25% and 69.99%±1.02% (mean±SD) through rat skin and 92.69%±2.22% and 53.51%±2.11% (mean±SD) through cadaver skin for EE and MPA, respectively.",Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),%,53.51,226880,DB00977,Ethinyl Estradiol
,22018130,T(max),The in vivo results showed prolonged T(max) of 36 h for both EE and MPA after transdermal administration compared to oral route (2 h).,Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),h,36,226881,DB00977,Ethinyl Estradiol
,22018130,T(max),The in vivo results showed prolonged T(max) of 36 h for both EE and MPA after transdermal administration compared to oral route (2 h).,Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22018130/),h,2,226882,DB00977,Ethinyl Estradiol
,29403920,overall recoveries,"The overall recoveries for 17-desacetyl norgestimate and 17-desacetyl norgestimate D6 were 96.30% and 93.90%, respectively.",Quantification of 17-desacetyl norgestimate in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403920/),%,96.30,227400,DB00977,Ethinyl Estradiol
,29403920,overall recoveries,"The overall recoveries for 17-desacetyl norgestimate and 17-desacetyl norgestimate D6 were 96.30% and 93.90%, respectively.",Quantification of 17-desacetyl norgestimate in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403920/),%,93.90,227401,DB00977,Ethinyl Estradiol
,29403920,total run time,The total run time was 4.5 min.,Quantification of 17-desacetyl norgestimate in human plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403920/),min,4.5,227402,DB00977,Ethinyl Estradiol
,16550733,Cmax,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[ng] / [ml],9.8,229682,DB00977,Ethinyl Estradiol
,16550733,AUC0-infinity,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[h·ng] / [ml],72.9,229683,DB00977,Ethinyl Estradiol
,16550733,AUC0-infinity,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[h·pg] / [ml],758,229684,DB00977,Ethinyl Estradiol
,6887930,half-life of total radioactivity elimination,"The half-life of total radioactivity elimination was 14-18 h in the rat and rhesus monkey, but longer (43 and 78 h, i.v. and oral respectively) in the baboon.","Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887930/),h,14-18,230212,DB00977,Ethinyl Estradiol
,6887930,half-life of total radioactivity elimination,"The half-life of total radioactivity elimination was 14-18 h in the rat and rhesus monkey, but longer (43 and 78 h, i.v. and oral respectively) in the baboon.","Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887930/),h,43,230213,DB00977,Ethinyl Estradiol
,6887930,half-life of total radioactivity elimination,"The half-life of total radioactivity elimination was 14-18 h in the rat and rhesus monkey, but longer (43 and 78 h, i.v. and oral respectively) in the baboon.","Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887930/),h,78,230214,DB00977,Ethinyl Estradiol
,6887930,half-life,"In the dog, the elimination phase could not be distinguished from the distribution phase and had a half-life of 2 h.","Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887930/),h,2,230215,DB00977,Ethinyl Estradiol
,6887930,half-life of unchanged,"The half-life of unchanged moxestrol elimination was shorter and very similar in the rhesus, baboon and human (6.6, 7.5 and 8.2 h respectively) and only 1.4 h in the dog.","Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887930/),h,6.6,230216,DB00977,Ethinyl Estradiol
,6887930,half-life of unchanged,"The half-life of unchanged moxestrol elimination was shorter and very similar in the rhesus, baboon and human (6.6, 7.5 and 8.2 h respectively) and only 1.4 h in the dog.","Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887930/),h,7.5,230217,DB00977,Ethinyl Estradiol
,6887930,half-life of unchanged,"The half-life of unchanged moxestrol elimination was shorter and very similar in the rhesus, baboon and human (6.6, 7.5 and 8.2 h respectively) and only 1.4 h in the dog.","Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887930/),h,8.2,230218,DB00977,Ethinyl Estradiol
,6887930,half-life of unchanged,"The half-life of unchanged moxestrol elimination was shorter and very similar in the rhesus, baboon and human (6.6, 7.5 and 8.2 h respectively) and only 1.4 h in the dog.","Pharmacokinetics and metabolism of moxestrol in animals--rat, dog and monkey. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6887930/),h,1.4,230219,DB00977,Ethinyl Estradiol
,16213451,flow rate,The flow rate was 1.0 ml/min and the total run time was 5.0 min.,Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high performance liquid chromatography with tandem mass spectrometry--experiences on developing a highly selective method using derivatization reagent for enhancing sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213451/),[ml] / [min],1.0,230396,DB00977,Ethinyl Estradiol
,16213451,total run time,The flow rate was 1.0 ml/min and the total run time was 5.0 min.,Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high performance liquid chromatography with tandem mass spectrometry--experiences on developing a highly selective method using derivatization reagent for enhancing sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213451/),min,5.0,230397,DB00977,Ethinyl Estradiol
,509953,half-lives,"Following the intravenous administration of the same dose of EE, plasma concentrations of the steroid declined biexponentially, the two half-lives being 0.83 and 6.75 hours.",An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/509953/),h,0.83,230597,DB00977,Ethinyl Estradiol
,509953,half-lives,"Following the intravenous administration of the same dose of EE, plasma concentrations of the steroid declined biexponentially, the two half-lives being 0.83 and 6.75 hours.",An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/509953/),h,6.75,230598,DB00977,Ethinyl Estradiol
,509953,oral bioavailability,Comparison of the results of the intravenous and oral administration of the steroid suggested that its oral bioavailability is 42%.,An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/509953/),%,42,230599,DB00977,Ethinyl Estradiol
,7813219,Kd,"The proportion of gestodene bound to SHBG was consistently higher than that observed for 3-ketodesogestrel, and this undoubtedly reflects the higher affinity of SHBG for gestodene (Kd = 1.2 nM at 37 degrees C) when compared to 3-ketodesogestrel (Kd = 4.7 nM at 37 degrees C).",Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813219/),nM,1.2,231265,DB00977,Ethinyl Estradiol
,7813219,Kd,"The proportion of gestodene bound to SHBG was consistently higher than that observed for 3-ketodesogestrel, and this undoubtedly reflects the higher affinity of SHBG for gestodene (Kd = 1.2 nM at 37 degrees C) when compared to 3-ketodesogestrel (Kd = 4.7 nM at 37 degrees C).",Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813219/),nM,4.7,231266,DB00977,Ethinyl Estradiol
,7813219,total serum levels,"It also probably accounts, in part, for the much higher total serum levels of gestodene (8.58 nmol/L) when compared to 3-ketodesogestrel (2.37 nmol/L) during the treatment cycles.",Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813219/),[nM] / [l],8.58,231267,DB00977,Ethinyl Estradiol
,7813219,total serum levels,"It also probably accounts, in part, for the much higher total serum levels of gestodene (8.58 nmol/L) when compared to 3-ketodesogestrel (2.37 nmol/L) during the treatment cycles.",Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7813219/),[nM] / [l],2.37,231268,DB00977,Ethinyl Estradiol
,2723113,peak plasma concentration,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ng] / [ml],103,233096,DB00977,Ethinyl Estradiol
,2723113,peak plasma concentration,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ng] / [ml],100,233097,DB00977,Ethinyl Estradiol
,2723113,time of peak,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,2.40,233098,DB00977,Ethinyl Estradiol
,2723113,time of peak,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,1.87,233099,DB00977,Ethinyl Estradiol
,2723113,elimination half-life,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,10.1,233100,DB00977,Ethinyl Estradiol
,2723113,elimination half-life,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,10.2,233101,DB00977,Ethinyl Estradiol
,2723113,total clearance,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ml] / [kg·min],3.70,233102,DB00977,Ethinyl Estradiol
,2723113,total clearance,"Mean pharmacokinetic variables for doxylamine in control and oral contraceptive groups were: peak plasma concentration, 103 vs 100 ng/ml; time of peak, 2.40 vs 1.87 hours after dosage, elimination half-life, 10.1 vs 10.2 hours; and total clearance, 3.70 vs 3.88 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ml] / [kg·min],3.88,233103,DB00977,Ethinyl Estradiol
,2723113,peak plasma concentration,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ng] / [ml],63.7,233104,DB00977,Ethinyl Estradiol
,2723113,peak plasma concentration,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ng] / [ml],73.8,233105,DB00977,Ethinyl Estradiol
,2723113,time of peak,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,2.7,233106,DB00977,Ethinyl Estradiol
,2723113,time of peak,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,2.2,233107,DB00977,Ethinyl Estradiol
,2723113,elimination half-life,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,6.0,233108,DB00977,Ethinyl Estradiol
,2723113,elimination half-life,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),h,5.1,233109,DB00977,Ethinyl Estradiol
,2723113,total clearance,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ml] / [kg·min],21.8,233110,DB00977,Ethinyl Estradiol
,2723113,total clearance,"Mean pharmacokinetic variables for diphenhydramine in control and oral contraceptive groups were: peak plasma concentration, 63.7 vs 73.8 ng/ml; time of peak, 2.7 vs 2.2 hours after dosage; elimination half-life, 6.0 vs 5.1 hours; and total clearance, 21.8 vs 25.5 ml/min/kg.",Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723113/),[ml] / [kg·min],25.5,233111,DB00977,Ethinyl Estradiol
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,13.8,233249,DB00977,Ethinyl Estradiol
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,13.3,233250,DB00977,Ethinyl Estradiol
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,25.9,233251,DB00977,Ethinyl Estradiol
,27138968,half-life,"Mean half-life was similar in the presence and absence of tofacitinib: 13.8 and 13.3 hours, respectively, for EE; 25.9 and 25.4 hours, respectively, for LN.",Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138968/),h,25.4,233252,DB00977,Ethinyl Estradiol
,8737765,area under the curve,"Following the first (second) intravenous administration, the mean area under the curve was 2.54 (2.67) ng.h.ml-1.",Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737765/),[h·ng] / [ml],2.54,233454,DB00977,Ethinyl Estradiol
,8737765,terminal half-life,"The terminal half-life and mean residence time were 9.7 (9.6) h and 10.5 (10.1) h, respectively.",Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737765/),h,9.7,233455,DB00977,Ethinyl Estradiol
,8737765,mean residence time,"The terminal half-life and mean residence time were 9.7 (9.6) h and 10.5 (10.1) h, respectively.",Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737765/),h,10.5,233456,DB00977,Ethinyl Estradiol
,8737765,steady-state volume of distribution,The steady-state volume of distribution was 4.3 (3.9) 1.kg-1 and the clearance was 7.0 (6.6) ml.min-1.kg-1.,Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737765/),[1] / [kg],4.3,233457,DB00977,Ethinyl Estradiol
,8737765,clearance,The steady-state volume of distribution was 4.3 (3.9) 1.kg-1 and the clearance was 7.0 (6.6) ml.min-1.kg-1.,Influence of repeated oral doses of ethinyloestradiol on the metabolic disposition of [13C2]-ethinyloestradiol in young women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8737765/),[ml] / [kg·min],7.0,233458,DB00977,Ethinyl Estradiol
,2737742,peak plasma levels,In the women taking 1 mg NET-acetate containing pills peak plasma levels ranging from 6.2 to 20.8 ng/ml were observed at 1 hr whereas with 500 micrograms pill they ranged from 2.0 to 6.5 ng/ml and the peak was noted at 4 hr.,Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737742/),[ng] / [ml],6.2 to 20.8,237231,DB00977,Ethinyl Estradiol
,2737742,peak plasma levels,In the women taking 1 mg NET-acetate containing pills peak plasma levels ranging from 6.2 to 20.8 ng/ml were observed at 1 hr whereas with 500 micrograms pill they ranged from 2.0 to 6.5 ng/ml and the peak was noted at 4 hr.,Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737742/),[ng] / [ml],2.0 to 6.5,237232,DB00977,Ethinyl Estradiol
,22133660,maximum serum concentration (C(max)),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[pg] / [ml],51.3,239964,DB00977,Ethinyl Estradiol
,22133660,area under the curve(0-168 h),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[h·ng] / [ml],6.26,239965,DB00977,Ethinyl Estradiol
,22133660,area under the curve(0-168 h),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[pg] / [ml],2400,239966,DB00977,Ethinyl Estradiol
,22133660,area under the curve(0-168 h),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[h·ng] / [ml],317,239967,DB00977,Ethinyl Estradiol
,22133660,steady-state concentration (C(ss48-168 h)),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[pg] / [ml],35.7,239968,DB00977,Ethinyl Estradiol
,22133660,steady-state concentration (C(ss48-168 h)),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[h·ng] / [ml],317,239969,DB00977,Ethinyl Estradiol
,22133660,steady-state concentration (C(ss48-168 h)),"During the third week of AG200-15 use, mean (±standard deviation) maximum serum concentration (C(max)), area under the curve(0-168 h) and steady-state concentration (C(ss48-168 h)) for EE were 51.3 ± 17.3 pg/mL, 6.26 ± 2.46 ng h/mL and 35.7 ± 14.5 pg/mL, respectively; for LNG, the corresponding values were 2400 ± 1140 pg/mL, 317 ± 159 ng h/mL and 1847 ± 930 pg/mL, respectively.","Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22133660/),[pg] / [ml],1847,239970,DB00977,Ethinyl Estradiol
,9723818,terminal half-life,The harmonic mean terminal half-life decreased from 17 h to 13 h during concomitant ritonavir.,Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723818/),h,17,241063,DB00977,Ethinyl Estradiol
,9723818,terminal half-life,The harmonic mean terminal half-life decreased from 17 h to 13 h during concomitant ritonavir.,Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723818/),h,13,241064,DB00977,Ethinyl Estradiol
,9723818,steady-state ritonavir concentrations,"Mean steady-state ritonavir concentrations of 6.5 and 13.4 microg ml(-1) were observed at 0 and 4 h postdose, respectively.",Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723818/),[μg] / [ml],6.5,241065,DB00977,Ethinyl Estradiol
,9723818,steady-state ritonavir concentrations,"Mean steady-state ritonavir concentrations of 6.5 and 13.4 microg ml(-1) were observed at 0 and 4 h postdose, respectively.",Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9723818/),[μg] / [ml],13.4,241066,DB00977,Ethinyl Estradiol
,6846427,bioavailability,"The bioavailability of orally administered EE2 was about 60%, confirming the presence of a substantial first-pass effect.",The pharmacokinetics and metabolism of ethinyl estradiol and its three sulfates in the baboon. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846427/),%,60,244931,DB00977,Ethinyl Estradiol
,6846427,elimination phase half-lives,"The elimination phase half-lives of all four compounds were similar, ranging from 8.8 to 11.2 hours.",The pharmacokinetics and metabolism of ethinyl estradiol and its three sulfates in the baboon. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846427/),h,8.8 to 11.2,244932,DB00977,Ethinyl Estradiol
,10368079,areas under the plasma concentration curves (AUC(0-24h,"Compared with placebo, areas under the plasma concentration curves (AUC(0-24h, geometric means) decreased by 47% for both EE (from 1,677 to 886 pg.h/ml; p < 0.01) and LN (from 137 to 73 ng.h/ml; p < 0.01), during OCBZ treatment.",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[h·pg] / [ml],1,245147,DB00977,Ethinyl Estradiol
,10368079,areas under the plasma concentration curves (AUC(0-24h,"Compared with placebo, areas under the plasma concentration curves (AUC(0-24h, geometric means) decreased by 47% for both EE (from 1,677 to 886 pg.h/ml; p < 0.01) and LN (from 137 to 73 ng.h/ml; p < 0.01), during OCBZ treatment.",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[h·ng] / [ml],137,245148,DB00977,Ethinyl Estradiol
,10368079,Peak plasma EE concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[pg] / [ml],180,245149,DB00977,Ethinyl Estradiol
,10368079,Peak plasma EE concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[pg] / [ml],117,245150,DB00977,Ethinyl Estradiol
,10368079,peak plasma LN concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[ng] / [ml],10.2,245151,DB00977,Ethinyl Estradiol
,10368079,peak plasma LN concentrations,"Peak plasma EE concentrations decreased from 180 pg/ml during the placebo cycle to 117 pg/ml during the OCBZ cycle (p < 0.01), whereas peak plasma LN concentrations decreased from 10.2 to 7.7 ng/ml (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),[ng] / [ml],7.7,245152,DB00977,Ethinyl Estradiol
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,13,245153,DB00977,Ethinyl Estradiol
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,28.8,245154,DB00977,Ethinyl Estradiol
,10368079,half-lives,"The half-lives of EE and LN also decreased from 13.6 to 7.9 h (p < 0.01) and from 28.8 to 15.8 h, respectively (p < 0.01).",Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368079/),h,15,245155,DB00977,Ethinyl Estradiol
,25138681,Relative bioavailabilities,"Relative bioavailabilities for EE and GSD were 31% and 24% higher, respectively, for arm vs. abdomen.","Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138681/),%,31,245352,DB00977,Ethinyl Estradiol
,25138681,Relative bioavailabilities,"Relative bioavailabilities for EE and GSD were 31% and 24% higher, respectively, for arm vs. abdomen.","Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138681/),%,24,245353,DB00977,Ethinyl Estradiol
,20108652,maximum plasma concentrations (Cmax),The observed mean maximum plasma concentrations (Cmax) of ethinylestradiol were 124.96 pg/ml (test) and 129.12 pg/ml (reference).,Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),[pg] / [ml],124.96,245678,DB00977,Ethinyl Estradiol
,20108652,maximum plasma concentrations (Cmax),The observed mean maximum plasma concentrations (Cmax) of ethinylestradiol were 124.96 pg/ml (test) and 129.12 pg/ml (reference).,Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),[pg] / [ml],129.12,245679,DB00977,Ethinyl Estradiol
,20108652,Cmax,"In the case of chlormadinone acetate, Cmax averaged 6.9566 ng/ml (test) and 6.6663 ng/m (reference).",Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),[ng] / [ml],6.9566,245680,DB00977,Ethinyl Estradiol
,20108652,Cmax,"In the case of chlormadinone acetate, Cmax averaged 6.9566 ng/ml (test) and 6.6663 ng/m (reference).",Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),[ng] / [m],6.6663,245681,DB00977,Ethinyl Estradiol
,20108652,area under the plasma concentration-time curve (AUC(0-infinity)),The geometric means of area under the plasma concentration-time curve (AUC(0-infinity)) of ethinylestradiol were 1292.35 pg/ml x h (test) and 1380.49 pg/ml x h (reference).,Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),[pg] / [h·ml],1292.35,245682,DB00977,Ethinyl Estradiol
,20108652,area under the plasma concentration-time curve (AUC(0-infinity)),The geometric means of area under the plasma concentration-time curve (AUC(0-infinity)) of ethinylestradiol were 1292.35 pg/ml x h (test) and 1380.49 pg/ml x h (reference).,Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),[pg] / [h·ml],1380.49,245683,DB00977,Ethinyl Estradiol
,20108652,AUC(0-infinity),"For chlormadinone acetate, geometric means of AUC(0-infinity) were 53.322 ng/ml x h (test) and 58.111 ng/ml x h (reference).",Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),[ng] / [h·ml],53.322,245684,DB00977,Ethinyl Estradiol
,20108652,AUC(0-infinity),"For chlormadinone acetate, geometric means of AUC(0-infinity) were 53.322 ng/ml x h (test) and 58.111 ng/ml x h (reference).",Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),[ng] / [h·ml],58.111,245685,DB00977,Ethinyl Estradiol
,20108652,tmax,The median of tmax of ethinylestradiol was 1.5 h for both test and reference and the median of tmax of chlormadinone acetate 1.0 h (test) and 1.5 h (reference).,Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),h,1.5,245686,DB00977,Ethinyl Estradiol
,20108652,tmax,The median of tmax of ethinylestradiol was 1.5 h for both test and reference and the median of tmax of chlormadinone acetate 1.0 h (test) and 1.5 h (reference).,Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),h,1.0,245687,DB00977,Ethinyl Estradiol
,20108652,Plasma elimination half-lives (t1/2),"Plasma elimination half-lives (t1/2) of ethinylestradiol were 14.96 h (test) and 15.41 h (reference) and of chlormadinone acetate 56.63 h (test) and 56.17 h (reference), respectively.",Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),h,14.96,245688,DB00977,Ethinyl Estradiol
,20108652,Plasma elimination half-lives (t1/2),"Plasma elimination half-lives (t1/2) of ethinylestradiol were 14.96 h (test) and 15.41 h (reference) and of chlormadinone acetate 56.63 h (test) and 56.17 h (reference), respectively.",Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),h,15.41,245689,DB00977,Ethinyl Estradiol
,20108652,Plasma elimination half-lives (t1/2),"Plasma elimination half-lives (t1/2) of ethinylestradiol were 14.96 h (test) and 15.41 h (reference) and of chlormadinone acetate 56.63 h (test) and 56.17 h (reference), respectively.",Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),h,56.63,245690,DB00977,Ethinyl Estradiol
,20108652,Plasma elimination half-lives (t1/2),"Plasma elimination half-lives (t1/2) of ethinylestradiol were 14.96 h (test) and 15.41 h (reference) and of chlormadinone acetate 56.63 h (test) and 56.17 h (reference), respectively.",Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20108652/),h,56.17,245691,DB00977,Ethinyl Estradiol
,2004528,peak EE levels,"Mean peak EE levels, 1350 pg/ml vs 91 pg/ml (p less than 0.001), were achieved 360 minutes and 90 minutes (p less than 0.01), after administration of the eutectic and reference formulation, respectively.",Absorption of oral ethinylestradiol is delayed by its eutectic mixture with cholesterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004528/),[pg] / [ml],1350,246728,DB00977,Ethinyl Estradiol
,2004528,peak EE levels,"Mean peak EE levels, 1350 pg/ml vs 91 pg/ml (p less than 0.001), were achieved 360 minutes and 90 minutes (p less than 0.01), after administration of the eutectic and reference formulation, respectively.",Absorption of oral ethinylestradiol is delayed by its eutectic mixture with cholesterol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2004528/),[pg] / [ml],91,246729,DB00977,Ethinyl Estradiol
,7371408,half-life,"After this event, an apparently terminal monoexponential decline was eventually established with a half-life of 13.1 h.",The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371408/),h,13.1,255124,DB00977,Ethinyl Estradiol
,7371408,volume of distribution,"As a result of EHC, the volume of distribution was increased by 60% to 6.0 1.Kg-1 but it does not appear that any significant accumulation of EE would occur during multiple dosing.",The pharmacokinetics of a large (3 mg) oral dose of ethynylestradiol in women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371408/),[1] / [kg],6.0,255125,DB00977,Ethinyl Estradiol
,17879972,IC(50),The IC(50) in ATRA of the ATRA emulsion for the Caco-2 carcinoma cells was 3.8 microg/mL lower than 6 microg/mL of the ATRA solution.,Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879972/),[μg] / [ml],3.8,256703,DB00977,Ethinyl Estradiol
,17879972,IC(50),The IC(50) in ATRA of the ATRA emulsion for the Caco-2 carcinoma cells was 3.8 microg/mL lower than 6 microg/mL of the ATRA solution.,Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879972/),[μg] / [ml],6,256704,DB00977,Ethinyl Estradiol
,17879972,IC(50),"The IC(50) of the emulsion for the HepG2 carcinoma cells was 2.8 microg/mL, while IC(50) was not achieved with the ATRA solution over the test concentration range.",Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17879972/),[μg] / [ml],2.8,256705,DB00977,Ethinyl Estradiol
,19882745,flow rate,The flow rate and detection wavelength were 1.0 mL/min and 230 nm.,Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),[ml] / [min],1.0,259927,DB00977,Ethinyl Estradiol
,19882745,detection wavelength,The flow rate and detection wavelength were 1.0 mL/min and 230 nm.,Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),,230,259928,DB00977,Ethinyl Estradiol
,19882745,limits of detection,"The correlation coefficients were greater than 0.9995 within 0.08-50 microg/mL for levonorgestrel and 0.12-50 microg/mL for quinestrol, and the limits of detection were 0.02 and 0.05 microg/mL for levonorgestrel and quinestrol, respectively.",Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),[μg] / [ml],0.02,259929,DB00977,Ethinyl Estradiol
,19882745,limits of detection,"The correlation coefficients were greater than 0.9995 within 0.08-50 microg/mL for levonorgestrel and 0.12-50 microg/mL for quinestrol, and the limits of detection were 0.02 and 0.05 microg/mL for levonorgestrel and quinestrol, respectively.",Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),[μg] / [ml],0.05,259930,DB00977,Ethinyl Estradiol
,19882745,recovery,Average recovery ranged from 92.5 to 96.3% and inter-day RSDs were less than 7.56%.,Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),%,92.5 to 96.3,259931,DB00977,Ethinyl Estradiol
less,19882745,RSDs,Average recovery ranged from 92.5 to 96.3% and inter-day RSDs were less than 7.56%.,Development and validation of a HPLC method for determination of levonorgestrel and quinestrol in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19882745/),,7,259932,DB00977,Ethinyl Estradiol
,29228469,flow rate,"The chromatographic analysis was performed on an Acquity UPLC HSS Cyano column, 100 Å (50 × 2.1 mm, 1.8 μm), column using gradient mobile phase, acetonitrile and 2.0 mm ammonium trifluoroacetate at 0-1.7 min (65:35, v/v) and 1.8-2.7 min (95:5, v/v) with 0.250 mL/min flow rate.",Simultaneous determination of etonogestrel and ethinyl estradiol in human plasma by UPLC-MS/MS and its pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29228469/),[ml] / [min],0.250,267302,DB00977,Ethinyl Estradiol
,1445483,Cmax,"During cycle one, Cmax, AUC(0-4h) and AUC(0-24h) values on day 1 were 1.9 +/- 0.7 ng/ml, 3.9 +/- 1.3 ng.ml-1.h and 12.4 +/- 5.7 ng.",Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445483/),[ng] / [ml],1.9,267380,DB00977,Ethinyl Estradiol
,1445483,AUC(0-4h),"During cycle one, Cmax, AUC(0-4h) and AUC(0-24h) values on day 1 were 1.9 +/- 0.7 ng/ml, 3.9 +/- 1.3 ng.ml-1.h and 12.4 +/- 5.7 ng.",Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445483/),[h·ng] / [ml],3.9,267381,DB00977,Ethinyl Estradiol
,1445483,AUC(0-24h),"During cycle one, Cmax, AUC(0-4h) and AUC(0-24h) values on day 1 were 1.9 +/- 0.7 ng/ml, 3.9 +/- 1.3 ng.ml-1.h and 12.4 +/- 5.7 ng.",Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1445483/),ng,12.4,267382,DB00977,Ethinyl Estradiol
,10771454,tmax,The tmax for levonorgestrel was approximately 0.5 h longer.,Ziprasidone and the pharmacokinetics of a combined oral contraceptive. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10771454/),h,0.5,267673,DB00977,Ethinyl Estradiol
,25295716,area under the concentration-time curve (AUC) ratio,"In study 1, average daily exposure to EE was similar for treatments P and M; the mean daily area under the concentration-time curve (AUC) ratio of treatment P vs. treatment M for EE was 1.06 (90% confidence interval (CI): 0.964 - 1.16), indicating average daily delivery similar to oral administration of 0.019 - 0.023 mg EE.",Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25295716/),,1.06,269035,DB00977,Ethinyl Estradiol
,25295716,AUC ratio,"The mean AUC ratio of treatment P vs. treatment M for unbound GSD was 0.820 (90% CI: 0.760 - 0.885), indicating average daily delivery from the patch of 0.057 - 0.066 mg GSD.",Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25295716/),,0.820,269036,DB00977,Ethinyl Estradiol
,9871424,area under the plasma concentration-time curve (AUC0-infinity),"The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·ng] / [l],6580,269060,DB00977,Ethinyl Estradiol
,9871424,area under the plasma concentration-time curve (AUC0-infinity),"The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·ng] / [l],5970,269061,DB00977,Ethinyl Estradiol
,9871424,AUC0-infinity,"No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·μg] / [ml],41.1,269062,DB00977,Ethinyl Estradiol
,9871424,AUC0-infinity,"No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·μg] / [ml],59.6,269063,DB00977,Ethinyl Estradiol
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],880,269574,DB00977,Ethinyl Estradiol
,3082590,AUC,Prior to sodium valproate therapy the mean AUC for EE2 was 880 +/- 109 pg/ml X h (+/- S.E.) and for levonorgestrel it was 29.1 +/- 2.9 ng/ml X h (n = 4).,The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.1,269575,DB00977,Ethinyl Estradiol
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[pg] / [h·ml],977,269576,DB00977,Ethinyl Estradiol
,3082590,AUC,"Between two and four months after sodium valproate therapy the mean AUC figures had not changed significantly, the figure for EE2 being 977 +/- 130 pg/ml X h and for levonorgestrel 29.2 +/- 1.9 ng/ml X h (p greater than or equal to 0.1 in each case).",The lack of effect of sodium valproate on the pharmacokinetics of oral contraceptive steroids. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3082590/),[ng] / [h·ml],29.2,269577,DB00977,Ethinyl Estradiol
,23228503,time to maximum drug concentration (Tmax,"For plasma EE levels, median time to maximum drug concentration (Tmax, 24-48 h) and mean maximum concentration (Cmax, 47.9-61.5 pg/mL) were similar among application sites.","Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228503/),h,24-48,270278,DB00977,Ethinyl Estradiol
,23228503,maximum concentration (Cmax,"For plasma EE levels, median time to maximum drug concentration (Tmax, 24-48 h) and mean maximum concentration (Cmax, 47.9-61.5 pg/mL) were similar among application sites.","Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228503/),[pg] / [ml],47.9-61.5,270279,DB00977,Ethinyl Estradiol
,23228503,Tmax,"For plasma LNG levels, median Tmax (72-120 h) and mean Cmax (1436-1589 pg/mL) were similar across application sites.","Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228503/),h,72-120,270280,DB00977,Ethinyl Estradiol
,23228503,Cmax,"For plasma LNG levels, median Tmax (72-120 h) and mean Cmax (1436-1589 pg/mL) were similar across application sites.","Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23228503/),[pg] / [ml],1436-1589,270281,DB00977,Ethinyl Estradiol
,1154455,sensitivity,"The sensitivity is 18 pg/ml, recovery 86.5%, and precision 10.9% (coefficient of variation).",Radioimmunoassay of unconjugated plasma ethynylestradiol in women given a single oral dose of ethynylestradiol or mestranol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1154455/),[pg] / [ml],18,270422,DB00977,Ethinyl Estradiol
,17258945,run time,"The LC run time is at least 6 min, enabling analysis of only about 100 samples a day.",A semi-automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258945/),min,6,271149,DB00977,Ethinyl Estradiol
,17258945,run time,In the present work the throughput was greatly improved by employing a semi-automated sample preparation process involving liquid-liquid extraction and derivatization with dansyl chloride followed by UPLC separation on a small particle size column achieving a run time of 2.7 min.,A semi-automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258945/),min,2.7,271150,DB00977,Ethinyl Estradiol
